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Introduction 
 
SECTION 1: INTRODUCTION 
Although a variety of delivery systems are being developed for different routes of 
administration like the oral, parenteral, nasal, and transdermal, the oral route remains 
attractive for drug delivery because this mode of administration is an easy, convenient, non-
invasive and familiar method of drug delivery. The common oral dosage forms include:  
liquid mixtures like solutions, suspensions, solid dosage forms like tablets and capsules and 
liquid filled capsules etc. However, patients at the extremes of age, such as children and the 
elderly, often experience difficulty in swallowing solid oral dosage forms. For these patients 
the drugs are mostly provided in liquid dosage forms such as emulsions and suspensions. 
These dosage forms usually lead to perceptible exposure of the active drug ingredient to taste 
buds and this is a very serious problem when the drug has an extremely unpleasant or bitter 
taste.  
 The bitter taste of the drugs, which are orally administered, is disadvantageous in 
several aspects. Taste is an important parameter governing the compliance. “The worse the 
taste of the medication, the better the cure” was once the prevailing attitude. A change in 
patient attitude and development of taste masking technique has reversed this opinion. 
Patients now expect and demand formulations that are pleasantly, or at least tolerably, 
flavoured. The disagreeable taste of drugs causes difficulties in swallowing (dysphagia) or 
causes patients to avoid their medication thereby resulting in low compliance of patients. 
Conventional taste masking techniques such as use of sweetener, amino acids, flavouring 
agents are often unsuccessful in masking the taste of the highly bitter drugs like quinine, 
barberin, antibiotics like levofloxacin, ofloxacin, sparfloxacin, ciprofloxacin, cefuroxime 
axetil, erythromycin, and clarithromycin. Thus taste masking technologies are considered 
important and developed by many researchers. 1 
The current work is concerned with pharmaceutical compositions containing the 1-
acetoxyethyl ester of cefuroxime, which has the approved name Cefuroxime axetil. The 
presence of 1-acetoxyethyl esterifying group results in significant absorption of the 
compound from the gastro-intestinal tract, whereupon the esterifying group is hydrolysed by 
enzymes present to yield the antibiotically active acid. Cefuroxime axetil has therefore 
extended the valuable therapeutic potential of cefuroxime by making available a form of 
antibiotic which may be administered orally. 
A convenient means of presenting antibiotics for oral administration is in the form of 
granules which may be administered as a solution or suspension. Syrups are particularly 
convenient for oral administration of antibiotics to children. They are particularly aimed at 
patients with nausea, vomiting, motion sickness and institutionalised patients.  However 
Cefuroxime axetil has an extremely bitter taste which is long lasting and this remains a 
challenge2 
1.1 DRY SYRUP  
Dry syrups are oral reconstitutable suspensions commercially available as dry 
mixtures that require the addition of water at the time of dispensing. 
TABLE 1: Commonly used ingredients in dry syrups  
Frequent Infrequent 
Suspending agent Anti caking Agent 
Wetting agent Flocculating agent 
Sweetener Solid diluents 
Preservative Antifoaming agent 
Flavour Granule binder 
Buffer Granule disintegrant 
Colour Antioxidant 
 Lubricant  
 
Advantages of Dry syrup 
1. Easy to formulate. 
2. Convenient method of administration for paediatrics, geriatrics, convalescent patient. 
3. Dissolution and bioavailability is more as it bypasses disintegration process.  
4. More palatable formulation for administration of bitter antibiotics.  
5. They have the advantage of both solid and liquid dosage forms, as they remain solid 
during storage, which aid in avoiding the physical stability problems like viscosity 
changes, conversion of polymorphic form, incompatibility, crystal growth, caking of 
dosage forms and when transform into liquid, has bioavailability.  
6. Reduces the weight of final product 
1.2. BACKGROUND 
Sense of taste 3,4,5,6 
Taste is a survival mechanism, alerting us to potentially harmful or potentially 
nutritious substances. We process taste at three levels: the receptor level, the circuit level, and 
the perceptual level. At the receptor level are approximately 10,000 chemoreceptors or taste 
buds, residing primarily on the tongue, with some delocalized receptors at the back of the 
throat. These receptors fall into five primary categories: bitter, sour, umani, salt, and sweet, 
with grouped receptors dissipated over the surface of the tongue for each stimulus. Sweet 
signals carbohydrates or certain amino acids. Sour characterizes vitamins. Salt detects needed 
minerals. Umani indicates protein and amino acids. In general, we experience these tastes as 
pleasant. Bitter sensation, however, is often unpleasant, suggesting alkaline water, alkaloid 
poisons, and spoiled foods. APIs, of course, usually fit into the bitter category. 
Chemoreceptors for taste and olfaction (smell) respond to chemicals in an aqueous 
environment. Chemicals dissolved in saliva excite the taste receptors of the mouth, and 
airborne chemicals dissolved in epithelial mucus excite the olfactory receptors of the nose. 
The senses are complementary, with smell and taste working together to respond to, and more 
narrowly define, the same stimuli3.  
 
Taste depends on physiological and psychological factors. Physiological properties 
such as temperature and texture, clearly affect the perception of taste (consider the limited 
appeal of a cold cup of coffee). Human taste also appears to change with age. Many children 
dislike fresh vegetables, yet grow to enjoy them in adult life. Psychological factors can also 
influence taste perception: a childhood memory of badly formulated cough medicine can 
significantly modify taste perception of a modern formulation. Such factors underscore the 
role of taste in manufacturing a product that achieves patient compliance. Culture influences 
perceived palatability.  
Market research has revealed standard combinations of specific sweeteners with 
relevant flavours and colours, which may vary by country and target market. National 
favourites include “green tea” in Japan, “bubblegum” in the United States, “citrus” notes in 
Europe, and “licorice” in Scandinavia. A bubblegum or cherry flavour married with a red 
colour and high intensity sweetener may suit a US pediatric market, while a less intense 
sweetener may be more appropriate for Japan. Similarly, a mint flavour coupled to a white 
unit may be a more traditional approach for an adult market. Regardless of the flavour system 
used, the challenge is how to deliver unpleasant compounds (APIs) while maintaining patient 
acceptability, efficacy, and compliance. Several formulation approaches may mask an 
unpleasant tasting API.4,5 
Threshold for taste is the minimum concentration of a substance that evokes perception 
of a taste. 
TABLE: 2.SPECIFIC AREA OF TONGUE AND THRESHOLD CONCENTRATION 
FOR PRIMARY SENSATIONS6 
TASTE AREA OF TONGUE THRESHOLD 
CONCENTRATION 
Sweet(sucrose) Tip of tongue 0.5% 
Sour(Hcl) Sides of tongue 0.007% 
Salt(Nacl) Tip and sides of tongue 0.25% 
Bitter(Quinine) Back of tongue 0.00005% 
 
1.3. TECHNIQUES OF  TASTE  MASKING  
Taste masking techniques 
To achieve the goal of taste abatement of bitter or unpleasant taste of drug, various 
techniques have been reported.3 
1. Addition of flavouring and sweetening agents. 
2. Microencapsulation / Coating with inert agents 
3. Ion‐exchange resins 
4. Inclusion complexation 
5. Granulation 
6. Adsorption 
7. Prodrug approach 
8. Bitterness inhibitor and potentiators 
9. Multiple emulsion technique 
10. Liposome preparation 
11. Gel formation 
12. Solid dispersions  
13. Molecular complex 
14. Mass extrusion 
15. pH modifiers 
16. Miscellaneous approaches  
 
1. Addition of flavours and sweeteners 3,4 
Addition of flavours & sweeteners is the most simplest approach for taste masking 
especially in the case of paediatric formulation. Flavouring and perfuming agents can be 
obtained from either natural or synthetic sources. Natural products include fruit juices, 
aromatic oils such as peppermint and lemon oils, herbs, spices and distilled fractions of these. 
They are available as concentrated extracts, alcoholic or aqueous solutions, syrups or spirit4. 
Clove oil has been found to be a good taste masking component for a number of medicinal, 
because of its spicy and anaesthetic effect. Aspartame is a prominent sweetener for bitterness 
reduction. A concentration of as small as 0.8% was effective in reducing the bitterness of a 
25% formulation of acetaminophen. Acesulfame potassium is an artificial sweetener which  
is 180-200 times sweeter than sucrose and as sweet as aspartame. Lactose, Saccharin, 
Sucralose are some of the commonly used sweeteners. This approach is also used to improve 
the aesthetic appeal of the product especially to make it more attractive for paediatric patient 
as well as used for the liquid formulation & the chewable tablets. Cooling effect of certain 
flavouring agent aids in reducing perception of bitterness. A combination of flavouring 
agents are usually employed. 
 
 
TABLE 3: RELATIVE SWEETENESS OF COMMONLY USED SWEETENERS 
 
Sweetening 
Agents                             
Relative sweeteness* Comment 
Aspartame      200 Not very stable in solution 
Acesulfame potassium 137‐200 Bitter after taste if used in 
higher concentration 
Cyclamate 40 Banned 
Glycerrhizin 50 Moderately expensive 
Lactose 0.16 Large amount required 
Manitol 0.60 Negative heat of solution 
Saccharin   450 Unpleasent after taste 
Sucrose 1 Most commonly used 
Sucralose 600 Synergistic sweetening 
effect 
            . 
 *Sucrose is taken as a standard of 1 for comparison. 
 
  
2. Microencapsulation 
 
Microencapsulation is a process by which very tiny droplets or particles of liquid or 
solid material are surrounded or coated with a film or polymeric material.7 Coating is an 
extremely useful technique to completely mask a bitter drug, while at the same time, not 
adversely affecting the intended drug release profile8. Any nontoxic polymer that is insoluble 
at pH 7.4 and soluble at acidic pH, would be an acceptable alternative for taste masking.9 
Only soluble portion of the drug can generate the sensation of taste. Coating the active drug 
with a polymeric film creates a physical barrier between the drug and the taste buds and 
reduces its solubility in saliva thus taste could be masked.10 
 
Techniques of microencapsulation are: 
• Air suspension 
• Coacervation‐phase separation 
• Spray drying and spray congealing 
• Solvent evaporation 
• Multiorifice ‐ centrifugal process 
• Pan coating 
• Interfacial polymerisation 
The air suspension coating process is the most commonly used method. It can be 
described as an upward moving, expanded, fluidized bed in central portion of the coating 
chamber coupled with a downward‐moving, more condensed fluidized bed on the periphery 
of the column. Three types of air suspension coater are available, namely, top spray coater, 
wurster bottom spray coater and tangential spray coater. The coating polymers should be such 
that it prevents the release of active agent in the oral cavity, following per oral intake, but 
allows it in stomach or small intestine where the drug is expected to be absorbed. Polymers, 
which are mainly insoluble at salivary pH 6.8 but readily, dissolve at gastric fluid pH 1.2 
could be a good candidate for taste masking.10  
3. Ion exchange resin 
Ion exchange resins are synthetic inert insoluble cross-linked organic polymers or 
polyelectrolytes consisting of a hydrocarbon network to which ionisable groups are attached 
and they have the ability to exchange their labile ions for ions of equal charge present in the 
solution with which they are in contact. Being high molecular weight water insoluble 
polymers, the resins are not absorbed by the body and are therefore inert. The long-term 
safety of ion exchange resins, even while ingesting large doses as in the use of 
cholestyramine to reduce cholesterol is established.7  They contain positively or negatively 
charged functional group and are thus classified as either anionic or cationic exchangers. 
Within each category, they are classified as strong or weak, depending on their affinity for 
capable counter ions3. These insoluble ion exchange resins may be supplied in case of cation 
exchangers as sodium, potassium or ammonium salts and of anion exchangers usually as the 
chloride. Charged drugs are normally loaded on to ion exchange resins by two methods, viz, 
column method and batch method. 
Column method 
In this method a highly concentrated drug solution is passed through a column of resin 
particles. Since the reaction is an equilibrium phenomenon, maximum potency and efficiency 
is best obtained by the column method. 
 
Batch method 
In this method the drug solution is agitated with a quantity of resin particles until 
equilibrium is established. 
 
Most of the bitter drugs have amine as a functional group, which is the cause of their 
obnoxious taste. If the functional groups are blocked by complex formation the bitterness of 
the drug reduces drastically. A drug: resin complex is made from the bitter drugs & ion - 
exchange resins. The nature of the drug: resin complex is such that the average pH of 6.7 and 
cation concentration of about 40 meq/ lit in saliva are not able to break the drug: resin 
complex but it is weak enough to be broken down by the hydrochloric acid present in the 
stomach. Thus the drug: resin complex is absolutely tasteless and stable, with no after taste, 
but at the same time its bioavailability is not affected.11 
 
Classification of Ion Exchange Resins11 
There are four major types of ion exchange resins available today: 
• Strongly acidic cation exchange resins with sulfonic acid functionality e.g. Dowex 50, 
Amberlite-120 and Sodium polystyrene sulfonate. 
• Weakly acidic cation exchange resins with carboloxylic functionality e.g. Amberlite 
IPR-88, Amberlite IPR-64 & IPR-64M and Amberlite IRC-50. 
• Strongly basic anion exchange resins with quaternary ammonium functionality e.g. 
Dowex1, Amberlite IR400. 
• Weakly basic anion exchange resins with secondary and tertiary amine functionality 
e.g. Amberlite IR 4B, Dowex 2, polyamine methylene resin. 
 
Equilibrium phenomenon12 
The principal properties of these resins are their exchange capacity to exchange its 
insoluble ions with those in solution. Soluble ions may be removed from the solution through 
exchange with the counter ions absorbed on the resin as illustrated in this equation: 
Resin- Drug+ + X+ Resin                     X+ + Drug+ 
Resin- Drug+ + Y+ Resin                     Y+ + Drug+ 
Where X and Y are ions in the gastrointestinal tract. 
Re-SO3 – Na+ + drug+                                         Re-SO3 _ drug+ + Na+ 
Re-N(CH3) 3 +Cl + + drug+                                      Re-N(CH3)3+ drug- + Cl- 
Strong acid cation resins (sulfonated styrenedivinyl benzene copolymer products) can 
be used to mask the taste of basic drugs having bitter taste, as they function throughout the 
entire pH range. Weak acid cation exchange resins function at the pH values above 6. 
Similarly, strong base anion exchange resin function throughout the entire pH range, while 
the weak base anion exchange resins function well below pH 7.13  
The ion-exchange resins suitable for use in the pharmaceutical preparations consist of 
a pharmacologically inert organic or inorganic matrix. The organic matrix may be synthetic 
(e.g., polymers or copolymers of acrylic acid, methacrylic acid, sulfonated styrene, sulfonated 
divinylbenzene), or partially synthetic (e.g., modified cellulose and dextrans). The matrix can 
also be inorganic, e.g., silica gel, or aluminosilicates, natively charged or modified by the 
addition of ionic groups. The covalently bound salt forming groups may be strongly acidic 
(e.g., sulfonic or sulfate acid groups), weakly acidic (e.g., carboxylic acid), strongly basic 
(e.g., quaternary ammonium), weakly basic (e.g., primary amine), or a combination of acidic 
and basic groups.  
Once the selection of resin is made the next step involves preparation of its complex 
with drug. Following steps are involved in the preparation of resinate:11 
• Purification of resin by washing with ethanol and water. 
• Changing of ionic form of IER might occasionally be required to convert resin from 
one form to another, if it doesn’t have desired counter ions. Na+ form of resin can be 
converted to H+ by soaking the resin with HCl. 
The drug: resin complexation process depends on several factors, which can affect the 
percent complexation of drug with resin, which are 
9 Effect of mixing time on Complexation 
9 Effect of Activation of ion exchange resin 
9 Effect of pH 
9 Effect of Temperature 
9 Effect of Mode of mixing 
9 Effect of swelling time 
9 Effect of concentration of loading solution 
 
Drug release from drug: resin complex14 
(Resinate) depends upon two factors: 
• The ionic environment (i.e. pH and electrolyte concentration) within the 
gastrointestinal tract. 
• The properties of resin. 
• Selection of resin 
• If drug is an acid, then use an anion exchange resin that has functionality such as 
amine and quaternary ammonium salt. If the drug is a base, then use a cation 
exchange resin, which has functionality such as sulfonic acid or carboxylic acid 
4. By inclusion complex formation16  
In inclusion complex formation, the drug molecules fits into the cavity of a 
complexing agent ie; the host molecule forming a stable complex. The complexing agent is 
capable of masking the bitter taste of the drug by either decreasing its oral solubility on 
ingestion or decreasing the amount of drug particles exposed to taste buds thereby reducing 
the perception of bitter taste. Van der Waals forces are mainly involved in inclusion 
complexes. Betacyclodextrin is most widely used complexing agent for inclusion type 
complexes. It is sweet, nontoxic, cyclic oligosaccharide obtained from starch. Strong bitter 
taste of carapentane citrate syrup was reduced to approximately 50% by preparing a 1:1 
complex with cyclodextrin.  The cyclodextrin itself is slightly sweet substance.  
 The cavity of CD is occupied by water molecules (about 13–14% w/w) both in 
crystalline state as well as in aqueous solution. Roughly half of this water is so-called ‘crystal 
water’ and the other half is ‘inclusion water’. The ‘crystal water’ is located and bound 
between the adjacent CD molecules, while ‘inclusion water’ is included into the hydrophobic 
cavity of CD. Hydrophobic drugs form complex by replacing ‘inclusion water’ while easily 
migrating (hydrophilic, well soluble) drugs form complex, assuming replacement of ‘crystal 
water’. CD is the ‘host’ molecule and an important component of the ‘driving force’ for the 
inclusion complex formation is the substitution of high enthalpy water molecules by the 
‘guest’ molecules. As the guest molecule is included into the CD molecule, which is 
enwrapped into a hydrate shell, the interaction of the guest molecule with cell membranes 
and receptors is considerably inhibited, resulting in reduced cytotoxicity or reduced taste. 17 
  
 5. Granulation18,19 
 Mixture of bitter medicaments and sweeteners, hydrophobic polymers, lipids or waxes 
can be processed by dry, wet and melt granulation techniques to prepare taste masked oral 
solid or liquid dosage forms. Bertelsen et al. (2006) described the melt granulation to achieve 
the taste masking of calcium-containing compounds like calcium carbonate. Melt granulation 
of a calcium-containing compound with a sugar alcohol as a binding agent resulted in 
granules with an acceptable taste and mouth feel. 
 Granulation is a less expensive, rapid operation and an easily scalable taste masking 
technology. Polymers, flavours and waxes have been used as granulating agents to achieve 
the taste masking of bitter medicaments. Liquid and low melting point waxes such as glycerol 
palmitostearate, glyceryl behenate and hydrogenated castor oil are commonly used 
ingredients during the granulation to achieve taste masking. Sugar alcohols and flavors are 
also added in the blend to increase the efficiency of taste masking. Both pH dependent and 
independent water insoluble polymers, especially the swelling polymers such as MCC and 
polycarbophil have been employed. During granulation, particle coating may remain 
incomplete. However, a swelling matrix phenomenon can reduce the overall diffusion of the 
bitter active. Thus, swellable polymers can give a better taste masking in granulation 
compared to non swellable polymers. Taste masked granules of bitter tasting drug 
pirenzepine and oxybutynin have been prepared by the extrusion using aminoalkyl 
methacrylate copolymer. 
6.  Adsorption18,19 
Adsorption involves preparing a solution of the drug and mixing it with an insoluble 
powder that will adsorb the drug, removing the solvent, drying the resultant powder, and then 
using this dried adsorbates in the preparation of the final dosage form. Many substrates like 
veegum, bentonite, silica gel and silicates can be used for the preparation of adsorbate of 
bitter drugs3. Adsorbates are commonly used with other taste masking technologies. The drug 
may be adsorbed or/and entrapped in the matrix of the porous component, which may result 
in a delayed release of the bitter active during the transit through the oral cavity thereby 
achieving taste masking. Kashid et al.(2007) developed a taste masked loperamide 
formulation where Loperamide and phenyl propanolamine have been adsorbed on 
magnesium aluminum silicate also known as Veegum F, by blending , and further granulating 
with hydrophobic polymers to achieve taste masking.18 
 
7.  Prodrug 
A prodrug is a chemically modified inert drug precursor, which upon 
biotransformation liberates the pharmacologically active parent drug. 
 
Prodrug for bitter taste masking 20 
Parent molecule    Reversible modification 
Chloramphenicol    Palmitate or phosphite ester 
Clindamycin     Alkyl ester 
Erythromycin     Alkyl ester 
Lincomycin     Phosphate or alkyl ester 
Tetracyclin     3,4,5‐Trimethoxy benzoate salts 
 
8. Bitterness inhibitors and potentiators 21       
Bitter substances are commonly hydrophobic in nature hence lipoprotein (PA‐LG) 
composed of phophatidic acid and β‐lactoglobulin can mask the target sites for bitter 
substances on the taste receptor membrane without affecting responses to salts, acids, sugars 
or sweet amino acids. Bitter taste of brucine, berberine, chloride, caffeine, denatonium 
benzoate, glycyl L‐leucine, L‐phenylalanine, naringin, propranolol hydrochloride, quinine 
hydrochloride, strychnine nitrate and theophylline  have been suppressed by lipoprotein. 
Potentiators increase the perception of the taste of sweeteners and mask the 
unpleasant after taste. Potentiators such as thaumatine, neohesperidine 
dihydrochalcone(NHDC) and glycyrrhizin can increase the perception of sodium or calcium 
saccharinates, saccharin, aspartyl-pheny-lalanine, acesulfame, cyclamates, and stevioside. 
Thaumatine was used with sugar alcohols to achieve the taste masking of bromhexine 
 
9.  Multiple emulsion technique22,23     
The w/o/w or o/w/o type multiple emulsions are vesicular systems in which active 
ingredients can be entrapped in internal phase. The entrapped substances can be transferred 
from internal phase to external phase through the ‘membrane phase’. This phase controls the 
release of drug from system. These system could be used for controlled‐release delivery of 
pharmaceuticals. If the system is stable enough for a reasonable shelf life, the formulation 
could also mask the taste of drug. Both w/o/w or o/w/o multiple emulsions of chloroquine 
phosphate have been prepared and reported to be partially effective in masking the bitter taste 
of drug.  
 
10. Gel formation24 
Water insoluble gelation on the surface of tablet containing bitter drug can be used for 
taste masking. Sodium alginate has the ability to cause water insoluble gelation in presence of 
bivalent metal ions. Tablet of amiprolose hydrochloride have been taste masked by applying 
a undercoat of sodium alginate and overcoat of calcium gluconate. In presence of saliva, 
sodium alginate react with bivalent calcium and form water insoluble gel and thus taste 
masking achieved. 
 
11) Solid dispersions25,26,27 
Specific interactions between poorly soluble drugs and hydrophilic polymers can 
increase the solubility of the drug; likewise specific interactions between the drug and the 
hydrophobic polymers might decrease the solubility of a drug.25 Recently solid dispersions 
were introduced as a taste masking technology. Tsau and Damani(1994) disclosed a drug-
polymer matrix composition to achieve the taste masking of dimenhydrinate. Amine or amido 
group of dimenhydrinate can have a physical and chemical interaction with the carboxylic 
acid and esters groups of copolymers such as shellac, zein and cellulose acetate phthalate.26 
Hydrophobic polymers and long chain fatty acids have been used to achieve the taste 
masking by solid dispersion. This approach usually requires a higher concentration of 
excipients compared to other taste masking techniques. Natural polymers such as shellac and 
zein, and enteric polymers like derivatives of acrylic acid polymers and phthalate are good 
choices to develop the taste masked solid dispersions. 
Solid dispersion of cephalosporins and cellulosic or methacrylic polymer was 
formulated to mask the unpleasant taste of the medicament. Additional excipients such as 
meglumine and magnesium silicate were added to increase the efficiency of taste masking 
 
  
TABLE 4: EXAMPLES OF DRUGS, EXCIPIENTS AND THE RATIO USED 
FOR TASTE MASKING 
Excipients Drugs % of excipients 
A methacrylic acid 
copolymer and a phthalate 
polymer 
Cefuroxime axetil Ratio of methacrylic acid 
copolymer to phthalate 
polymer is between 1:9 and 
9:1 and ratio of the polymers 
to the drug is at least 1:4 
Shellac  Crude drug Ratio of the polymers to the 
drug is 4:1 
Zein  Crude medicine 
extract 
 
Ratio of the polymers to the 
drug is between 2:1 and 4:1 
Higher fatty acids(stearic 
acid or 
palmitic acid) 
Levofloxacin or 
Ofloxacin 
Ratio of the drug to the fatty 
acids is between 1:0.3 to 1:4 
 
1) Melting method In this method, the drug or drug mixture and a carrier are melted together 
by heating. The melted mixture is cooled and solidified rapidly in an ice bath with vigorous 
stirring. The final solid mass is crushed and pulverized. 
2) Solvent method In this method, the active drug and carrier are dissolved in a common 
solvent, followed by solvent evaporation and recovery of the solid dispersion. 
3) Melting-solvent method In this method the drug in solution is incorporated into a molten 
mass of polyethylene glycol at a temperature below 700 ˚C without removing the solvent. 
 
12. Mass extrusion method (Dispersion coating)21 
This technology involves softening the active blend using the solvent mixture of water 
soluble polyethylene glycol, using methanol and expulsion of softened mass through the 
extruder or syringe to get a cylinder of the product into even segments using heated blade to 
form tablets. The dried cylinder can also be used to coat granules of bitter tasting drugs and 
thereby masking their bitter taste. 
 
13.  pH Modifiers19,28 
pH Modifying agents are capable of generating a specific pH microenvironment in 
aqueous media that can facilitate in situ precipitation of the bitter drug substance in saliva 
thereby reducing the overall taste sensation for liquid dosage forms like suspension. Redondo 
and Abanades (2003) developed taste masked liquid formulation of ibuprofen by using 
sodium saccharin and pH regulating agents. 
 
14. Taste masking using Liposomes:29  
Another way of masking the unpleasant taste of therapeutic agent is to entrap the drug 
into liposome. For example, incorporating into a liposomal formulation prepared with egg 
phosphatidylcholine masked the bitter taste of chloroquine phosphate in HEPES (N-2-
hydroxyethylpiperzine-N’- 2- ethane sulfonic acid) buffer at pH 7.2. 
15. Molecular complexes of drug with other chemicals:20 
             The solubility and adsorption of drug can be modified by formation of molecular 
complexes. Consequently lowering drug solubility through molecular complex formation can 
decrease the intensity of bitterness of drug. 
 
16.  Miscellaneous taste masking approaches:28   
• By effervescent agents:  
            Effervescent agents have been shown to be useful and advantageous for oral 
administration of drugs and have been employed for use as taste masking agents for dosage 
forms. 
• Rheological modification: 
            Increasing the viscosity with rheological modifier such as gums or carbohydrates can 
lower the diffusion of bitter substances from the saliva to the taste buds. 
• Continuous multipurpose melt Technology: 
              The CMT method was developed for the continuous granulation and coating of 
pharmacologically active substances.  This method could be successfully applied for taste 
masking of bitter drugs.  
1.4. FACTORS AFFECTING SELECTION OF TASTE MASKING TECHNOLOGY19 
A. Extent of Bitter Taste 
With aggressively bad tasting medicaments even a little exposure is sufficient to 
perceive the bad taste. For example, sweeteners could not achieve taste masking of oral 
formulation of ibuprofen due to its dominating taste. Coating is more efficient technology for 
aggressively bitter drugs even though coating imperfections, if present, reduce the efficiency 
of the technique 16 
 
 
B. Dose of Active Pharmaceuticals 
Dose of a drug may dictate whether a particular formulation strategy would be 
suitable to achieve taste masking. In paediatric formulations, the dose is small enough so as 
to allow the usage of flavouring agents to mask the taste of the medicine. For example, low 
dose palatable paediatric aspirin oral formulation was developed by adding sweeteners, but 
the same approach failed to address the problem of drugs like acetaminophen because of its 
high dose. In such cases, coating is preferred to achieve taste masking along with sweeteners 
to attain an acceptable final dosage form size 18. 
 
C. Drug Particle Shape and Size Distribution 
Particle characteristics of the drug would affect the taste masking process efficiency. 
Core materials with irregular shapes and small particle size lead to poor taste masking 
efficiency and varying dissolution of coated particles 18. Fines, abrasion and variable coating 
thickness can lead to situations wherein the taste mask coating is compromised. Multilayer 
coating using inner spacing layer to sequester the drug from taste masking layer helps to 
reduce or eliminate such coating imperfections. Taste masked granules of gatifloxacin and 
dextromethorphan were formulated by multilayer coating consisting of inner spacing layer 
followed by outer taste masking layer. 
 
D. Dosage Forms 
It is estimated that 50% of the population have problem of swallowing tablets, 
especially the paediatric and geriatric population. Chewable tablets and liquid oral dosage 
forms have been used to address these problems. For formulations which are swallowed 
unchewed: capsules, coated tablets and slowly disintegrating hard tablets have been used as 
preferred taste masking technologies. Chewable tablets and liquid oral formulations are 
preferable in case of large dose drugs for an ease of intake. Microencapsulation of the 
unpleasant tasting active agent with ethyl cellulose or a mixture of ethyl cellulose and 
hydroxypropyl cellulose or other cellulose derivatives has been used to provide chewable 
taste-masked dosage forms. 
 
However, this approach suffers from the disadvantage that the polymer coating 
releases the active agent in an inconsistent fashion and may not provide an immediate release. 
Moreover, coating is more suitable when the formulation is stored in a dry form. 
 
 
E. Drug Solubility 
Physicochemical properties of the drug play an important role in the selection of taste 
masking technology. For example, ondansetron has a relatively lower water solubility at 
higher pH, based on which a rapidly disintegrating taste masked composition of ondansetron 
was formulated by adding an alkalizing agent(sodium bicarbonate) to reduce the water 
solubility and the consequent taste perception.  
 
 
F. Ionic Characteristics of the Drug 
Ionic characteristics of drugs govern the selection of ion exchange resin polymers and 
the suitability of the drug candidate for this technology. For example, anionic polymers (e.g. 
alginic acid) are good candidates for cationic drugs like donepezil hydrochloride, and the 
cationic polymers are choice of excipients for anionic drugs like sildenafil. 
 
To conclude, there are a number of technologies available which effectively mask the 
objectionable taste of drugs but require skilful application which does not affect the 
bioavailability of drug. With application of these techniques and proper evaluation of taste 
masking effect, one can improve product preference to a large extent. Moreover, the 
development of taste masking methodology requires great technical skill, and 
experimentation. 
 
  
  
 
 
 
 
 
 
 
 
 
Aim and Objectives 
SECTION 2:  AIM AND OBJECTIVE  
The aim of this study is formulation development and evaluation of taste masked Cefuroxime 
Axetil Oral suspension. Many conventional tablets are available in adult strength and the 
administration of accurate dosage for children is critical. Oral suspension can be formulated 
in paediatric strength. Swallowing difficulty is another drawback with conventional tablet 
dosage form, that can be overcome by Oral suspension formulation. 
Cefuroxime Axetil is a second generation cephalosporin antibiotic. It is used in the 
treatment of uncomplicated urinary tract infections, respiratory tract infections, otitis media, 
and Lyme disease. 
The taste of Cefuroxime Axetil is extremely bitter. Marketed preparations of 
Cefuroxime Axetil currently available are not completely devoid of bitterness problem. So 
children cannot tolerate the bitter taste of the drug and vomit out during administration. The 
formulation of taste masked oral suspension was aimed to administer Cefuroxime Axetil in a 
more palatable form to obtain a “patient-friendly dosage form” especially for paediatric 
patients and hence that will increase the patient compliance.   In the present work the problem 
is addressed and better taste masking methodologies were used for rectification. 
 
OBJECTIVE 
 To design and formulate a taste masked formulation of Cefuroxime axetil Oral 
Suspension  
 To apply different taste masking technology 
 To evaluate the oral suspension  
 To optimise the formula for the suspension  
 To take a scale up batch of the same.  
 To charge the oral suspension for stability testing. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plan of Work  
  
SECTION 3: PLAN OF WORK 
1 Literature survey 
2 Preformulation studies 
Evaluation of API for its 
I. Physical parameters such as organoleptic properties, particle 
size, solubility, bulk density, tapped density, angle of repose, 
compressibility index, hausner ratio. 
II. Analytical parameters such as assay and water content 
III. Drug excipient compatibility 
DSC 
Physical Compatibility 
3. Innovator product evaluation 
4. Development stages  
 Trials based on  
a. Sweeteners and flavours 
b. Coating with stearic acid 
c. Complexation  
• Inclusion complex with beta cyclodextrin  
5. Formulation evaluation   
I. Physical evaluation 
a) Fill weight 
b) Pourability  
c) Viscosity 
d) Mouth feel 
e) Taste 
f) Flavour 
g) Angle of repose 
h) Bulk density 
II. Analytical evaluation  
a) Dissolution   
b) p H 
c) Assay  
 6. Optimisation of formula 
7. Taste evaluation   
8. DSC study 
9. pH stability study 
10. Scale up study 
11. Stability studies 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature 
SECTION 4: REVIEW OF LITERATURE 
Mukherji et al30 developed a taste masked dry syrup formulation prepared by 
dissolving the active ingredient, the methacrylic acid copolymer and the phthalate polymer in 
a solvent and recovering the composition thereof. In this study the ratio of drug to polymer 
was 1:1 in a solvent mixture of acetone and water was 1:1. The granules thus obtained 
released 100% of the drug from the matrix within 45 minutes in Ph 6.8 buffer.    
Pandey Shivanand et al 31 formulated taste masked fast disintegrating tablets of 
lisinopril. The beta cyclodextrins were useful for masking the taste as well as enhanced the 
solubility of drug. The complexation was done by slurry method in a ratio of 1:5. The 
technology was found to be more effective.         
Gedam Shweta S.32, Tapar K. K, Borse M. D and Ghuge R. A. Developed taste 
masked microparticles of diphenhydramine using HPMC and PVP as polymer by spray 
drying technique and concluded that the amount of drug and polymer has its own significant 
complementary role in enhancement of the process rather than having an exclusive effect. 
Birhade et al 33reported the utilisation of cyclodextrin binary systems as an approach 
for taste masking of rizatriptan benzoate. The complexation was done by physical and 
kneading mixture methods in different ratios. The binary systems showed effective taste 
masking without any limiting effect on the drug release.  
Alija Uzunovic 34and Edina Vranic conducted a study on the stability of cefuroxime 
axetil oral suspension at different temperature storage conditions. Determination of 
cefuroxime was performed by dissolution testing. It concluded that oral suspension preserves 
its stability for 10 days after reconstitution under room and refrigerated conditions. 
Donn KH et al 35conducted a study to determine if the cefuroxime axetil formulations 
are bioequivalent. They concluded that bioequivalence between the suspension and tablet was 
not observed and further the addition of surfactant in the suspension did not alter the 
bioavailability of the formulation   
M Krishnakumar 36et al developed a stable taste masked coated, non disintegrating  
pellets comprising the steps of reducing the particle size of one or more cephalosporins, said 
pellets being further coated with one or more layers of film coating to achieve taste masking      
Fernandez G, et al 37developed a formulation in particulate form, the particles being 
provided with integral coatings of lipid or mixture of lipids which are insoluble in water and 
which disperse or dissolve on contact with gastrointestinal fluid. Applicants have discovered  
that the sweetner system and texture modifier act synergistically to overcome both the bitter 
taste and also improve mouth feel thereby aiding patient compliance. The simultaneous use of 
the texture modifier helps to provide a creamier texture improving mouth “feel” and, in 
addition, reducing the number of lipid coated particles left in the mouth when the preparation 
is swallowed further reducing the bitter taste effect. 
Abdul Rehman Khan et al 38developed an oral composition of cefuroxime axetil in 
tablet form where the drug is contained in the core, coated with double layered film coat. The 
first film coat serves to mask the bitter taste of drug and the second film coat serves to delay 
the rupture time beyond 40 seconds.  
Nighute A.B., et al39 prepared the microcrystal of cefuroxime axetil and concluded 
that reduced size of drug particles in presence of the surfactant on the surface of drug 
microcrystals are responsible for enhanced solubility, dissolution velocity along with 
stability. HPMC E-15LV was found to be the best surfactant in their study.  
Sihshu et al (2001)40 reported the formulation of bitter taste masked liquid oral 
suspension of nalidixic acid. In this work drug was taste masked by microencapsulation 
technique. In this a pH sensitive polymer  E-100 and then taste masked  microsphere were 
formulated into liquid oral suspension.   .    
D.P Venkesh et al.41 developed a formulation of bitter taste masked oral dispersible 
tablet of antiemetic drug Odansetron by complexation with ion exchange resin. They 
described that taste masked drug polymer complex eliminate the extreme bitterness of the 
drug to make orodispersible dosage form palatable  using cationic exchange resin like Indion 
204,Indion 234 and Thulsion 334   
Thoshihiko Izhizaka et al 41studied the suppression of enhanced bitterness intensity 
of clarithromycin dry syrup mixed with an acidic powder. Accordingly a best way to achieve  
taste masking was to first administer clarithromycin dry syrup  mixed with chocolate jelly 
which has a neutral pH followed by  L-carbocystein suppression. 
Sohi H. et al. 42reviewed that any pharmaceutical formulation with a pleasing taste 
would definitely be preferred over a competitor’s product and would translate into better 
compliance and therapeutic value for the patient and more business and profits for the 
company. The desire of improved palatability in these products has prompted the 
development of numerous formulations with improved performance and acceptability. This 
article reviews the earlier applications and methodologies of taste masking and discuss the 
most recent developments and approaches of bitterness reduction and inhibition for oral 
pharmaceuticals 
P. Dellamonica43 has compiled informations regarding the chemistry, microbiology, 
pharmacology, pharmacokinetics, antimicrobial activity, clinical studies, drug interactions, 
therapeutic uses in detail. Science direct 
S.B. Sateesha et al 44prepared stable and palatable norfloxacin suspension 
formulation for oral administration. The granules were prepared by coating with different 
levels of acrycoat E100-40. The interaction between norfloxacin and eudragit E100 was 
analysed by FTIR. Rheological studies reveal a plastic thixotropy of the reconstituted dry 
syrup. In vitro dissolution studies performed at Ph 1.2 showed satisfactory dissolution rate for 
all the formulations. Drug content of reconstituted liquid suspension on day 1 and at day 5 
were within the limits. Stability studies of dry suspension formulation conducted at 40 ± 2˚C 
for three months were found to be stable and percentages of drug remaining were higher than 
98% of initial concentration. 
Santosh Shelke et al 45developed a simple accurate cost effective and reproducible 
spectrophotometric method for the estimation of cefuroxime axetil in bulk and 
pharmaceutical dosage form. UV spectrophotometric method, which is based on 
measurement of absorption at maximum wavelength 281nm.The percentage recovery of 
cefuroxime axetil ranged from (99.97 ± 0.3969) in pharmaceutical dosage form. The 
developed method was validated with respect to linearity, accuracy (recovery), precision and 
specificity. Beers law was obeyed in the concentration range of 4-28µg/ml having line 
equation y = 0.0346x + 0.0566 with correlation coefficient of 0.9999. Results of the analysis 
were validated statistically and by recovery study. 
Diego A. Chiappetta et al 46developed indinavir pediatric anti- HIV/AIDS 
formulations enabling convenient dose adjustment, ease of oral administration , and improved 
organoleptic properties by means of the generation of drug loaded microparticle made of a 
polymer that is insoluble under intake conditions and dissolves fast in the stomach in order to 
completely release the active agent. Indinavir loaded microparticles made of a Ph- dependent 
polymeric excipient soluble at Ph<5, Eudragit E 100, were prepared using  double emulsion 
solvent diffusion technique and characterized.  
Alonso et al47 reported the encapsulation of cefuroxime axetil, a highly bitter drug, in 
Ph sensitive acrylic microspheres in order to formulate a suspension dosage form. The acrylic 
polymers used were eudragit E, eudragit RL100, eudragit L100-55. The cationic polymer 
eudragit E showed a negative interaction with cefuroxime axetil. The cationic polymer 
eudragit L100-55 showed a favourable release in alkaline Ph. The release of cefuroxime 
axetil was studied in basic media.  
Dantzig et al48showed that cefuroxime axetil is hydrolyzed to cefuroxime in the 
intestinal lumen by the esterases reducing the cefuroxime axetil concentration in the lumen 
and resulting in reduced absorption, leading to low bioavailability of Cefuroxime axetil in 
humans. Cefuroxime axetil already has a low bioavailability of 32-50% and hence further 
reduction in the bioavailability due to the formulation aspects should be minimized. The taste 
masking formulations should be so designed that the bioavailability of the drugs is not 
compromised and the use of certain polymers like the enteric coatings should not affect the 
time to peak. Further the drug should be sufficiently absorbed to ensure effective therapeutic 
concentration in the plasma. 
Meyer et al.49 used prolamine, applied as single coating in weight ratio 5% to 100% 
relative to active substance being coated result in the production of a liquid suspension which 
effectively masked the taste of orally administered drugs which are extremely bitter. 
Prolamine coating does not restrict the immediate bioavailbility of the active substance 
Prolamine coating is effective in masking the taste of antibiotics, vitamins, dietary fibers, 
analgesic, enzymes, and hormones.  
Yajima et al.50 in their patent have described a composition comprising of a drug 
with unpleasant taste of polymer solution and D-crystals of monoglycerides.  Eudragit E (100 
g) was dissolved in melted stearic acid monoglyceride (600 g) and then Erythromycin (300 g) 
were added to the mixture to obtain a powder, which was again mixed with sorbitol, 
magnesium oxide and starch to give taste masked granules of Erythromycin.  
Danielson et al51. invented a dosage form comprising granules containing the 
histamine receptor antagonist which are provided with taste masking coating comprising a 
water insoluble, water permeable methacylate ester copolymer in which the coating is applied 
to the granules in an amount which provides a taste masking effect for a relatively short 
period during which the composition is being chewed by a patient but which allows 
substantially immediate release of the histamine receptor antagonist after the composition has 
been chewed and ingested.  
J. Park52 investigated an effect of excipients in Cefuroxime axetil (CFX) formulas. 
The tablets were manufactured including polymethacrylate, L-HPC, Lactose, Cellactose and 
croscarmellose sodium, sodium starch glycolate, corspovidon, magnesium trisillicate, 
magnesium stearate as diluents and concluded that, polymethacrylate, L-HPC and 
croscarmellose sodium inhibited the tendency of CFX to form a gel and provided good 
dissolution profiles than lactose, Cellactose, crospovidone and sodium starch glycolate. And 
it was found that L-HPC, polymethacrylate and croscarmellose sodium resulted in better 
dispersibility and dissolution rate than another diluents. The effect of excipients was 
evaluated by statistical coefficient with a dissolution test and its behaviour. 
Pateli A.R.,Vavia P.R53 prepared and evaluated taste masked famotidine formulation 
using beta cyclodextrin and reports that the complex with higher stability constant will 
usually require greater dilution to affect the release of drug; complex with lower stability 
constant will release the drug even at lower dilution (ie; oral cavity). Stability constant 
increasing effect of complexation with beta cyclodextrin results in effective taste masking.   
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SECTION 5: DRUG AND EXCIPIENT PROFILE 
 DRUG PROFILE54 
DRUG  :  Cefuroxime Axetil. 
STRUCTURAL FORMULA          : 
 
 
 
 
MOLECULAR FORMULA :         
C
20
H
22
N
4
O
10
S.  
MOLECULAR WEIGHT  :  510.48. 
CHEMICAL NAME   : Cefuroxime Axetil is a mixture of the 2  
diastereoisomers of (1RS)-1-(acetyloxy) ethyl(6R,7R)-
3-[(carbamoyloxy)methyl]-7-[[(Z)-2-(furan-2-yl)-2-
(methoxyimino) acetyl]amino]-8-oxo-5-thia-1-
azabicyclo [4.2.0]oct-2-ene-2-carboxylate. 
CATEGORY    : Second Generation Cephalosporin;              
Antimicrobial. 
DOSE : 250-500 mg every 12 hours.  
DESCRIPTION : A white or almost white powder. 
SOLUBILITY : Slightly soluble in water and ethanol. Soluble in 
acetone, ethyl acetate and methanol.  
MELTING POINT  :  135°C. 
PHARMACOKINETICS:  
Cefuroxime Axetil is absorbed from the Gastro intestinal tract and is rapidly 
hydrolysed in the intestinal mucosa and blood to Cefuroxime.  Peak plasma concentrations 
are reported about 2 to 3 hours after an oral dose. Cefuroxime is widely distributed into most 
body tissues and fluids, including pleural fluid, sputum, bone, synovial fluids, gall bladder, 
liver, kidney and bile. It crosses the placenta and is 33% to 50% protein-bound. The plasma 
half life is 1.3 hours. Cefuroxime is primarily excreted in urine by renal tubular   secretion 
and glomerular filtration.  Small amounts of Cefuroxime are excreted in bile and breast milk.  
MECHANISM OF ACTION:  
The cell walls of bacteria are essential for their normal growth and development. 
Peptidoglycan is a heteropolymeric component of the cell wall that provides rigid mechanical 
stability by virtue of its highly cross-linked latticework structure. Cefuroxime Axetil interfere 
with the synthesis of bacterial cell wall peptidoglycan by binding to specific penicillin-
binding proteins (PBPs) located inside the bacterial cell wall and causes Cell lysis.  
ANTI-MICROBIAL SPECTRUM:  
Cefuroxime is active against a wide range of Gram-positive and Gram-negative 
bacteria including Haemophilus influenzae, Enterobacter, Staphylococcus aureus, 
Streptococcus pneumoniae, Neisseria species and inactive against Pseudomonas aeruginosa. 
ADVERSE REACTIONS:  
Anaphylaxis, pseudomembranous colitis, nausea, vomiting, headache, dizziness, 
diarrhea, transient elevation of liver enzymes, over dose may cause cerebral irritation and 
convulsions. 
  
INDICATIONS:  
¾ Cefuroxime axetil is used in treating Upper and Lower respiratory tract infections, 
skin and soft tissue, urinary tract, bone and joint infections. 
¾ It is used to treat Gonorrhoea, otitis media, impetigo and meningitis.  
¾ It is also indicated in treating and preventing Lyme disease. 
CONTRAINDICATIONS:  
Contraindicated in patients with hypersensitivity to cefuroxime or other 
cephalosporins, severe renal impairment, pregnancy and lactation. 
DOSAGES:  
Oral suspension must be administered with food. 
A dose for children more than 3 months of age is 125 mg twice daily or 30 mg/kg 
twice daily given in 2 divided doses for 10 days. In case of pharyngitis and tonsillitis children 
over 3 months to 12 years of age 20mg/kg daily in 2 divided doses for 10 days  to a 
maximum of 500 mg daily. For respiratory tract infections and impetigo in Children 3 
Months to 12 Years of Age  30mg/kg daily should be given in 2 divided doses for 10 days. 
Lyme disease: Adults and Children above 12 years: 500 mg b.i.d. for 20 days. 
STORAGE:  
Preserve in air tight containers, protect from light and kept in cool dark place. 
MARKETED PRODUCTS:  
ZINNAT 125,250 mg/5ml 
OTHER FORMULATIONS:  
Cefuroxime Axetil is available in the market in various dosage forms including 
dispersible tablet, Tablets, Film coated tablets, Capsules.                                  
 
EXCIPIENT PROFILE 
BETA CYCLODEXTRIN55 
 
STRUCTURAL FORMULA : 
 
 
SYNONYMS    : Beta-cycloamylose; beta-dextrin,  
betadexum   
CHEMICAL NAME                    : β – cyclodextrin. 
EMPIRICAL FORMULA  : C42H70O35. 
MOLECULAR WEIGHT  : 1135. 
PHYSICAL STATE : Cyclodextrins occur as white, practically 
odorless, fine crystalline powders, having a 
slightly sweet taste. Some cyclodextrin 
derivatives occur as amorphous powders. 
SOLUBILITY : Soluble 1 in 200 parts of propylene glycol, 1 in 
50 parts of water at 20°C, 1 in 20 at 50°C, 
practically insoluble in acetone, ethanol (95%) 
and methylene chloride. 
MELTING POINT : 255-265°C. 
BULK DENSITY  : 0.523 g/ cm3. 
TAPPED DENSITY  : 0.754 g/ cm3. 
pH       : 5.0 – 8.0. 
STABILITY AND STORAGE     : It is stable material in solid state if 
 protected  from high humidity. 
 Cycodextrins should be  stored in 
 tightly sealed container, in a cool and 
 dry place. 
APPLICATIONS   : β-cyclodextrin is considered to be  
nontoxic when administered orally and has thus 
primary used in tablet and capsule formulation. 
It is used in the formulations to form  inclusion 
complexes for a wide range of drugs which 
ultimately results in improved bioavailability, 
solubility, masking unpleasant taste and 
sometimes conversion of a liquid to a solid 
material.  
INCOMPATIBILITIES : The activity of some antimicrobial preservatives 
in a aqueous solution can be reduced in the 
presence of cyclodextrins. 
 
XANTHAM GUM56 
SYNONYMS :  Corn sugar gum, ,Rhodogel,  
CHEMICAL NAME :  Xanthan gum 
MOLECULAR WEIGHT :  2,000,000 
PHYSICAL STATE  :  Xantham gum occurs as a cream or white 
colored, odorless, free flowing, fine powder.  
SOLUBILITY                    : Partially insoluble in ethanol and ether. Soluble 
in cold or warm water. 
MELTING POINT              : 260oC 
pH                                         : 6.8 (1%w/v aqueous solution) 
STABILITY AND STORAGE  
CONDITIONS  : Xantham gum is a stable material. Aqueous 
solutions are stable over a wide pH range (pH 3-
12). The bulk material should be stored in a well 
closed container in a cool, dry place. 
APPLICATIONS  : Stabilizing agent, suspending agent, viscosity 
increasing agent Xantham gum is widely used in 
oral and topical pharmaceutical formulations. It 
is used as a thickening and emulsifying agent. 
SAFETY  : Xantham gum is widely used in oral & topical 
pharmaceutical formulations. It is generally 
regarded as an essentially nontoxic and 
nonirritant. 
 
  
ASPARTAME56 
STRUCTURAL FORMULA : 
 
 
 
 
 
 
SYNONYMS : Aspartamum, Canderel, Natra Taste,  
  NutraSweet, Pal Sweet, Pal Sweet Diet. 
CHEMICAL NAME                     : N-α-L-Aspartyl-L-phenylalanine 1-methyl ester. 
EMPIRICAL FORMULA  : C14H18N2O5. 
MOLECULAR WEIGHT  : 294.31. 
PHYSICAL STATE : Aspartame occurs as an off white, almost 
odourless crystalline powder with an intensely 
sweet taste. 
SOLUBILITY : Slightly soluble in ethanol (95%); sparingly 
soluble in water. Solubility increases at higher 
temperature and at more acidic pH.  
MELTING POINT   : 246-247°C. 
BULK DENSITY : 0.5-0.7g/cm3 for granular grade; 0.2-0.4g/cm3 
for powder grade. 
 
 
TRUE DENSITY   : 1.347g/cm3. 
pH     : 4.5-6.0 (0.8% w/v aqueous solution). 
STABILITY AND STORAGE : Aspartame is stable in dry conditions. In the 
presence of moisture, hydrolysis occurs to form 
the degradation products L-aspartyl-L-
phenylalanine and 3-benzyl -6-carboxy methyl-
2, 5-diketopiperazine.The bulk material should 
be stored in a well closed container in a cool, 
dry place. 
APPLICATIONS : Aspartame is used as a intense sweetening agent 
in beverage products, food products, table-top 
sweeteners, and in pharmaceutical preparations 
including tablets, powder mixes and vitamin 
preparations. 
It enhances flavour systems and can be used    to 
mask some unpleasant taste characteristics. 
INCOMPATIBILITIES : Aspartame is incompatible with dibasic calcium 
phosphate and also with the lubricant 
magnesium stearate. Reactions between 
aspartame and sugar alcohols are also observed. 
  
SODIUM LAURYL SULFATE56 
 
STRUCTURAL FORMULA : 
 
 
SYNONYMS                                   :  Dodecyl sodium  sulfate, sodium mono lauryl 
sulfate, Empicol. 
CHEMICAL NAME                       : Sulfuric acid monododecyl ester sodium salt. 
EMPIRICAL FORMULA :         C12H25NaO4S. 
MOLECULAR WEIGHT : 288.38. 
PHYSICAL STATE : Sodium lauryl sulphate consists of white or 
cream to pale yellow coloured crystals, flakes or 
powder having a smooth feel, a soapy, bitter 
taste and a faint odour of fatty substances. 
SOLUBILITY : Freely soluble in water, giving an opalescent 
solution; practically insoluble in chloroform and 
ether. 
MELTING POINT   : 204-207°C. 
pH     : 7.0 – 9.5 (1% w/v aqueous solution). 
STABILITY AND STORAGE : Sodium lauryl sulphate is stable under normal 
storage conditions. However, in solution under 
extreme conditions, i.e, pH 2.5 or below, it 
undergoes hydrolysis to lauryl alcohol and 
sodium bisulphate. It should be stored in a well 
closed container in a cool, dry place. 
APPLICATIONS : Sodium lauryl sulphate is employed in a wide 
range of non-parenteral pharmaceutical 
formulations and cosmetics. 
It is a detergent and wetting agent effective in 
both alkaline and acidic conditions. 
INCOMPATIBILITIES : Sodium lauryl sulphate reacts with cationic 
surfactants causing loss of activity even in 
concentrations too low to cause precipitation. 
It is incompatible with dilute acids, calcium and 
magnesium ions. 
 
 
. 
 
 
 
 
 
  
SUCROSE56 
STRUCTURAL FORMULA :  
 
SYNONYMS :    Beet sugar; cane sugar; a-D-glucopyranosyl-b-
D-fructofuranoside; 
                                                                 refined sugar; saccharose; saccharum; sugar. 
CHEMICAL NAME : b-D-fructofuranosyl-a-D-glucopyranoside 
EMPIRICAL FORMULA : C12H22O11 
MOLECULAR WEIGHT  : 342.30  
PHYSICAL STATE                      :  Sucrose occurs as colorless crystals, as  
Crystalline masses or blocks, or as a white 
crystalline powder; it is odorless and has a sweet 
taste. 
SOLUBILITY : soluble in water and practically insoluble in 
chloroform. 
MELTING POINT   : 160–1860C (with decomposition) 
BULK DENSITY   : 0.93 g/cm3. 
TAPPED DENSITY   : 1.03 g/cm3 
STABILITY AND STORAGE : Sucrose has good stability at room temperature 
and at moderate relative humidity. It absorbs up 
to 1% moisture, which is released upon heating 
at 900C. Sucrose caramelizes when heated to 
temperatures above 1600C. Dilute sucrose 
solutions are liable to fermentation by 
microorganisms but resist decomposition at 
higher concentrations, e.g. above 60% w/w 
concentration. Aqueous solutions may be 
sterilized by autoclaving or filtration 
APPLICATIONS   : Confectionery base; coating agent;  
granulation aid; suspending agent; sweetening 
agent; tablet binder; tablet and capsule diluent; 
tablet filler; therapeutic agent; viscosity-
increasing agent. 
INCOMPATIBILITIES  : Powdered sucrose may be contaminated  
with traces of heavy metals, which can lead to 
incompatibility with active ingredients, e.g. 
ascorbic acid. Sucrose may also be contaminated 
with sulphite from the refining process. With 
high sulfite content, color changes can occur in 
sugar-coated tablets; for certain colors used in 
sugarcoating the maximum limit for sulfite 
content, calculated as sulfur, is 1 ppm. In the 
presence of dilute or concentrated acids, sucrose 
is hydrolyzed or inverted to dextrose and 
fructose (invert sugar). Sucrose may attack 
aluminum closures. 
 
ISOPROPYL ALCOHOL56 
STRUCTURAL FORMULA : 
 
SYNONYMS                                 : Alcohol isopropylicus; dimethyl carbinol; IPA; 
isopropanol. 
CHEMICAL NAME   : Propan-2-ol. 
EMPIRICAL FORMULA  : C3H8O.  
MOLECULAR WEIGHT  : 60.1. 
PHYSICAL STATE : Isopropyl alcohol is a clear, colourless, volatile, 
flammable liquid with a characteristic, spirituous 
odour resembling that of a mixture of ethanol 
and acetone; it has a slightly bitter taste. 
SOLUBILITY : Miscible with benzene, chloroform, ethanol 
(95%), ether, glycerin, and water. Soluble in 
acetone; insoluble in salt solutions. 
BOILING POINT   : 88.5°C. 
STABILITY AND STORAGE        : Stable under ordinary conditions. Isopropyl 
alcohol should be stored in an air tight container 
in a cool, dry place. 
APPLICATIONS : Isopropyl alcohol is used in cosmetics and 
pharmaceutical formulations, primarily as a 
solvent in topical formulations. 
Isopropyl alcohol is also used as a solvent both 
for tablet film-coating and for tablet granulation, 
where the isopropyl alcohol is subsequently 
removed by evaporation.  
INCOMPATIBILITIES : Incompatible with oxidizing agents such as 
hydrogen peroxide and nitric acid, which cause 
decomposition.  
 
  
STEARIC ACID56 
STUCTURAL FORMULA             : 
 
SYNONYMS    : Acidum stearicum; Crodacid; Cristal G,                                       
Emersol,hystrene,Industrene,Kortacid1895 
Pristerene. 
CHEMICAL NAME   : Octadecanoic acid. 
EMPIRICAL FORMULA              :  C18H36O2 
MOLECULAR WEIGHT              :  284.47 
 
PHYSICAL STATE   : Stearic acid is a hard ,white or faintly  
yellow colored, Somewhat glossy,crystalline 
solid or a white or  yellowish white powder.it 
has a slight odor and taste. 
SOLUBILITY                               :    Freely soluble in benzene,carbon  
tetrachloride,  chloroform,and ether, soluble in 
ethanol(95%)                                                            
hexane and propylene glycol,practically 
insoluble in water. 
MELTING POINT   :  69-700c 
BULK DENSITY                        : 0.537 g/cm3 
TAPPED DENSITY                   : 0.571 g/cm3 
 
STABILITY AND STORAGE  : Stearic acid is a stable material. An  
antioxidant may also added to it. The bulk 
material should be stored in a well                                               
closed container in a cool, dry, place. 
APPLICATIONS                        : Stearic acid is widely used in oral and  
topical pharmaceutical formulations. It is
 mainly used in oral formulations as a  
tablet and capsule lubricant                       
although it may also be used as a binder or in 
combination with shellac as a tablet coating 
agent. In topical formulations, stearic acid is 
used as an emulsifying                        
and solubilizing agent. It is used as hardening 
agent in glycerin suppositories. It is also used in 
cosmetics and food products. 
INCOMPATIBILITIES        : Stearic acid is incompatible with most  
metal hydroxides and may be incompatible with 
reducing agents and   oxidizing agents. Ointment 
bases made with stearic acid may show evidence 
of drying out or lumpiness due to such a reaction 
when compounded with zinc or calcium salts. 
Stearic acid has been reported to cause pitting in 
the film coating of tablets when coated using an 
aqueous film coating technique.  
  
MICROCRYSTALLINE CELLULOSE56 
1.STRUCTURAL FORMULA     : 
 
 
 
2. NONPROPRIETARY NAME    :            
• BP  : Microcrystalline cellulose 
• JP         : Microcrystalline cellulose 
• PhEur   : Cellulosum microcrystallinum 
• USPNF : Microcrystalline cellulose 
 
3. SYNONYM   : Avicel ; Cellulose gel ; tabulose 
                                                         Crystalline cellulose; E460;  
Emcocel Fibrocel;vivacel 
4. CHEMICAL NAME                   :        Cellulose 
5. EMPIRICAL FORMULA         :        (c6H10O5)n  
6. MOLECULAR   WEIGHT        : ≈36000  where  n≈220. 
7. FUNCTIONAL CATEGORY    :       Adsorbent;suspending agent; 
capsule and tablet diluents ;  tablet disintegrant.  
 
8. PHYSICAL STATE  : It is a purified, partially depolymerised   
Cellulose that occurs white odourless, Tasteless, 
crystalline powder composed of porous 
particles. It is commercially available in 
different particle size and moisture grades which 
have different properties and applications. 
9. TYPICAL PROPERTIES:           
                  Density (bulk)            :        0.337 g/cm3 
                  Density (tapped)        :        0.478 g/cm3 
                  Density (true)            :        1.512-1.668 g/cm3 
                  Melting point            :        Chars at 260-270oC 
                  Moisture content      :        Less than 5% w/w 
 10. SOLUBILITY                       :        Slightly soluble in 5%w/v sodium  
Hydroxide solution,Practically  insoluble in 
water ,dilute acids,and most  Organic solvents. 
 11.STABILITY AND  
      STORAGE CONDITION    :       Microcrystalline     cellulose is  a  
stable, though hygroscopic material. The bulk 
material should be stored in in a well closed 
container in a cool,dry,place.  
 12. INCOMPATIBILITIES   : Incompatible with strong   
Oxidizing agents. 
 13. APPLICATIONS    : It is widely used in  
pharmaceuticals,  primarily as a binder/ diluents 
in oral tablet and capsule  formulations. Where it 
is used in both wet granulation and direct 
compression processes. Microcrystalline 
cellulose also has some lubricant  and 
disintegrant properties that make it useful in 
tableting. It is also used in cosmetics and food 
products. 
LACTOSE ANHYDROUS56 
1. NONPROPRIETARY NAME    :            
• BP        : Anhydrous lactose 
• JP         :  Anhydrous lactose 
• PhEur   : Lactosum anhydricum 
• USPNF : Anhydrous lactose 
2. SYNONYM                            : Milk sugar, pharmatose, tablettose                                                
3. CHEMICAL NAME  :  O-β-D-Galactopyranosyl- 
(1→4)-β-D-glucopyranose 
4. EMPIRICAL FORMULA : C12H22O11  
5. MOLECULAR   WEIGHT : 342.30 
6. FUNCTIONAL CATEGORY : Binding agent;  directly compressible   
tableting excipients, lyophilization aid,    tablet 
and capsule filler.                      
 7. PHYSICAL STATE  : White to off-white crystalline    particles  
or powder. 
 
8. TYPICAL PROPERTIES:   
                  Angle of repose          :     39o         
                  Density (bulk)            :      0.68g/cm3 
                  Density (true)             :      1.589 g/cm3 
                  Melting point             :      223.08◦C for anhydrous a-lactose; 
                                                             252.28◦C for anhydrous b-lactose; 
                                                              232.08◦C (typical) for commercial anhydrous  
    lactose 
                  Moisture content      :       contains  upto 1% w/w 
 9. SOLUBILITY    :      soluble in water; sparingly soluble  
in ethanol(95%) and ether. 
 10. STABILITY AND  
       STORAGE CONDITION     : Under humid conditions  
(80% relative humidity and above), mold 
growth may occur. On storage , lactose 
may develop a brown colouration, the 
reaction being  accelerated by warm, 
damp conditions. 
11. INCOMPATIBILITIES   : Lactose anhydrous is    
Incompatible with strong  Oxidizers. 
 
12. APPLICATIONS  : Anhydrous lactose can widely  
  used in direct compression   
  tabletting applications and as a  
  tablet and capsule filler and   
  binder. Anhydrous lactose due to  
  its low moisture content can be  
  used with moisture- sensitive  
  drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials & Methods 
 
SECTION 6: MATERIALS AND EQUIPMENTS USED 
MATERIALS  
TABLE 5: LIST OF MATERIALS USED AND THE SUPPLIERS AND 
MANUFACTURERS 
S.NO MATERIALS SUPPLIERS MANUFACTURERS 
1.  Cefuroxime axetil 
Dhanuka 
laboratories ltd, 
Haryana  
Dhanuka laboratories 
Ltd, Haryana 
2. Sucrose  Indras agencies  Eid Parry India Pvt Ltd  
3. Sucralose  
Kawarlal and 
Company , 
Chennai  
Unitech , China  
4. Aspartame  
Kawarlal and 
Company , 
Chennai 
The Nutrasweet 
Company, USA  
5. Acesulfame k  The Sunett The Nutrasweet Company, USA 
6. Xanthum gum  Signet chemicals  CP Kelco US Inc. USA 
7.         MCC MItutiyo,India MItutiyo,India 
8. 
 
Lactose anhydrous 
 
Signet chemicals CP Kelco US Inc. USA 
9. Tuttifrutti flavour K. P. Manish Global Ingredients  
Firmenich Aromatics . 
India  
10. Peppermint flavour K. P. Manish Global Ingredients  
Firmenich Aromatics . 
India 
11. Beta cyclodextrin Signet chemicals  Roquette , France 
12. Sodium lauryl sulphate  
Kawarlal 
excipients , 
Chennai 
Cognis Pharma  
14. Triethyl citrate Chemport India Pvt Ltd, Mumbai  
Chemport India Pvt 
Ltd, Mumbai 
15. Methylene chloride  Ponpure Chemicals Pvt Ltd 
Solvay Chemical 
International  
16. Iso propyl alcohol Nice chemicals, Cochin  
Nice chemicals, 
Cochin 
17. Citric acid  Amjal India Pvt Ltd ,  Ruskin Chemipharma 
 
 
 
 
EQUIPMENTS 
TABLE 6: LIST OF THE EQUIPMENTS USED AND THE MANUFACTURERS 
S.No 
Name of the 
Equipment 
Model of equipment Manufacturer 
1.  Weighing balance HJ - 3 Hercules Electronic Scales 
2.  
Mechanical 
homogeniser 
RQT  -  124  A 
Remi Elektrotechchnik Ltd., 
Mumbai 
3.  Tray dryer I- 0550 
Gem pharma Machineries, Navi 
Mumbai 
4.  Hot air oven STR - 392 
Servewell Instruments Pvt Ltd, 
Banglore 
5.  Bulk density apparatus I- 0576 Veego 
6.  Digital pH meter I -0372 Digisun Electronics Hyderabad 
7.  
Dissolution test 
apparatus 
TDL  -  08 L Electrolabs, Banglore 
8.  HPLC I- 0750 Shimadzu Corporation, Japan 
9.  Kf titrator I- 0378 Lasco laboratory services 
10.  Ultrasonicator I -  0412 PCI  Mumbai 
11.  
UV visible 
spectrophotometer 
I - 0319 Shimadzu Corporation, Japan 
12.  
Differential Scanning 
Calorimeter 
S- 0810 Mettler Laboratories 
13.  Stability chamber I - 0396 
Servewell Instruments Pvt Ltd, 
Banglore 
 
 
 
 
  
CONSTRUCTION OF STANDARD GRAPH FOR CEFUROXIME AXETIL 
PREPARATION OF 0.07 N HYDROCHLORIC ACID : 
Measure 5.95ml of hydrochloric acid in 1 litre standard volumetric flask and make up 
the volume using demineralized water. 
 
CALIBRATION OF STANDARD CURVE: 
Accurately weighed Cefuroxime axetil which is equivalent to 100 mg of cefuroxime 
in a 100ml standard volumetric flask and dissolved in methanol. The volume was made upto 
100ml using 0.07N Hydrochloric acid to obtain a stock solution-1(1000µg/ml).From this 
stock solution -1,10ml was pippetted out into a 100ml standard volumetric flask and made 
upto the mark using 0.07N Hydrochloric acid (stock solution-2).From this stock solution -
2,aliquots of 2ml,4ml,6ml,8ml,10ml,and 12ml,were pipetted out into a series of 100ml 
standard volumetric flasks and the volume was made upto the mark with 0.07N Hydrochloric 
acid to get drug concentration in the range of 2 to 12µg/ml.The absorbance of the resulting 
solution was then measured at 278nm using UV double beam spectrophotometer against 
0.07N Hydrochloric acid as blank.The standard curve was obtained by plotting 
concentration(µg/ml)values in X-axis and the absorbance values in Y-axis. 
TABLE 7: 
STANDARD CURVE DATA OF CEFUROXIME AXETIL 
 
Sl.No CONCENTRATION 
(µg/ml) 
ABSORBANCE 
at 278nm 
1 2 0.098 
2 4 0.188 
3 6 0.266 
4 8 0.375 
5 10 0.471 
6 12 0.563 
  
FIGURE-1 
 
Caliberation curve of cefuroxime axetil  
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SECTION 7 : METHODS AND PROCEDURE 
7.1 PREFORMULATION STUDIES 
 It can be defined as an investigation of physical and chemical properties of a drug substance 
alone and when combined with excipients. 
EVALUATION OF API 
7.1.1 Organoleptic Properties  
Organoleptic properties like colour, odour and taste of Cefuroxime Axetil were studied 
7.1.2 . Particle Size Analysis 
Particle size distribution of the drug was estimated by sieving method. The sieves are stacked 
on top of one another in ascending degrees of coarseness. The test powder, for example 50g, 
was placed on the top sieve. The nest of sieves was subjected to a standard period of 
agitation. The weight of material retained on each sieve was accurately determined. 
Percentage of powder retained on each sieve was calculated.  
7.1.3 Solubility    
Solubility is defined as the number of gram of substance which will dissolve in 100 grams of 
solvent at a stated temperature. The solubility of drug was studied in different solvents such 
as water, acetone, ethanol, sodium hydroxide, hydrochloric acid by measuring how many 
parts of solvent is required for one part of solid. 
Very soluble: 1 part of the substance is soluble in less than 1 part of the solvent. 
Freely soluble: 1 part of substance is soluble in 1 to 10 parts of solvent. 
Soluble: 1 part of substance is soluble in 10 to 30 parts of solvent. 
Sparingly soluble: 1 part of substance is soluble in 30-100 parts of solvent. 
Slightly soluble: 1 part of substance is soluble in 100 to 1,000 parts of solvent. 
Very slightly soluble: 1 part of substance is soluble in 1,000 to 10,000 parts of       
solvent. 
Practically insoluble or insoluble: More than 10,000 parts of solvent is required to 
dissolve 1 part of substance. 
7.1.4 Flow property    
Flow property of powder determines its flow from hopper while manufacturing. This is 
measured in terms of angle of repose, bulk density, tapped density, compressibility index, 
hausner ratio. 
Angle of repose57 : It is the maximum angle that can be obtained between the freestanding 
surface of a powder heap and the horizontal plane. The value gives the quantitative measure 
of the cohesive and frictional effects under low levels of external loading. 
                                              θ  =  tan -1(h/r) 
Where, 
            h is the height of the pile from the surface of the pile 
            r is the radius of the base of the pile formed. 
Bulk density58 : Bulk density is defined as powder mass divided by its bulk volume without 
any tapping. It is the density of the powder when loosely packed in a measuring cylinder. 
Powder bulk density depends primarily on particle size distribution, particle shape, and the 
tendency of particles to adhere to each other. Some particles may pack loosely, leading to 
fluffy and light powder, while others may contain smaller particles that sift between larger 
particles to fill the void, leading to dense and heavy powder. Bulk density is often used to 
calculate the batch size for blender. 
Weighed quantity of powder blend from each formulation was taken in a measuring cylinder 
and the initial volume of the powder blend in the measuring cylinder was noted. Bulk density 
of the powder blend was calculated by using the following formula:  
              Mass of the powder                 
Bulk density   =   
         Bulk Volume occupied 
 
Tapped density59 : Tapped density of a powder is the ratio of the mass of the powder to the 
volume occupied by the powder after it has been tapped for a defined period of time. 
Tapped density was measured by introducing the known quantity of powder into a graduated 
cylinder and carefully levelling off the powder without compacting it. The cylinder was 
mechanically tapped by placing on the bulk density apparatus. The volume was measured by 
tapping the powder blend for 500 times.  Then the tapping was done for 750 times and the 
tapped volume was noted. The tapped density was calculated by using the following formula:  
              Mass of the powder   
    Tapped density =    
              Tapped volume 
The compressibility index is a measure of the propensity of a powder to consolidate. As such, 
it is a measure of the relative importance of inter-particulate interactions. In a free-flowing 
powder, such interactions are generally less significant and the bulk and tapped densities will 
be closer in value. For poorer flowing materials, there are frequently greater interparticle 
interactions; bridging between particles often results in lower bulk density and a greater 
difference between the bulk and tapped densities. These differences in particle interactions 
are reflected in the compressibility index. 
The compressibility index (CI) and hausner ratio (HR) are also helpful in determining the 
flow characteristics. Compressibility index  has been proposed as an indirect measure of bulk 
density, size, surface area, moisture content and cohesiveness of material. Both of these are 
determined from bulk volume and tapped volume of a powder. 
          (bulk volume – tapped volume)  * 100 
  Carr’s compressibility index =  
        Bulk volume  
 
      Initial volume   
Hausner ratio  =   
          Final volume  
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 8: FLOW PROPERTY  
S.NO 
FLOW 
CHARACTER 
ANGLE 
OF 
REPOSE 
CARR’S 
INDEX 
HAUSNER’S 
RATIO 
1 Excellent 25– 30 1 –  10 1.0 – 1.11 
2 Good 31 – 35 11– 15 1.12 –  1.18 
3 Fair 36 – 40 16 – 20 1.19 – 1.25 
4 Passable 41 – 45 21 – 25 1.26 – 1.34 
5 Poor 46 – 55 26 – 31 1.35 – 1.45 
6 Very  poor 56 – 65 32 – 37 1.46 – 1.59 
7 Very very poor >66 >38 1.60 
 
7.1.5 HPLC Assay for cefuroxime axetil 
Mobile phase is degassed mixture of 0.2M Monobasic ammonium phosphate and methanol 
(620:380). 
Internal standard solution is a solution of acetanilide in methanol containing 5.4 mg per ml. 
Standard preparation : Transfer about 30 mg of the drug to a 25 ml volumetric flask, 
dissolve in methanol, dilute with methanol to volume and mix. Promptly transfer 10 ml of 
this solution to a 50 ml volumetric flask add 5 ml of internal standard solution and 3.8 ml of 
methanol, dilute with 0.2M Monobasic ammonium phosphate to volume and mix.  
Procedure: Separately inject equal volumes of the standard preparation and the assay 
preparation into the chromatograph, record the chromatograms, and measure the responses.  
The chromatogram is recorded at 278 nm.  
7.1.6 Water content  
The water content is determined titrimetrically by Karl Fischer titration.  
      
Titre volume × mean KF factor 
Water content =    
10   ×  weight of the sample  
 
  
7.1.7 DRUG- EXCIPIENT COMPATIBILITY 
Compatibility studies were performed by preparing blend of different excipients with drug 
and stored at 40°C/75%RH for one month. The blend was evaluated for every 15 days for 
changes like caking, liquefaction, discoloration and odour formation. 
 
TABLE 9: DRUG EXCIPIENT COMPATIBILITY 
SL.NO COMPOSITION QUANTITY 
RATIO 
(Drug:Excipient)
1 Cefuroxime axetil 1gm - 
2 Cefuroxime axetil + Beta cyclodextrin  2gm 1:1 
3 Cefuroxime axetil+ Eudragit L 100 2gm 1:1 
4 Cefuroxime axetil + Xanthum gum 2gm 1:1 
5 
Cefuroxime axetil + Colloidal Silicon 
Dioxide 
2gm 1:1 
6 Cefuroxime axetil + Purified Talc 2gm 1:1 
7 
Cefuroxime axetil + Sodium lauryl 
sulphate 
1.25gm 1:0.25 
8 Cefuroxime axetil +Aspartame 2gm 1:1 
9 Cefuroxime axetil +Sucralose 2gm 1:1 
10 Cefuroxime axetil + Acesulfame K 2gm 1:1 
11 Cefuroxime axetil + Sucrose 2gm 1:0.25 
12 Cefuroxime axetil + Peppermint flavor 1.25gm 1:0.25 
13 Cefuroxime axetil + Tutti frutti flavour 1.25gm 1:0.25 
14 Cefuroxime axetil + Citric acid  2gm 1:1 
15 Cefuroxime axetil + PVP K30 2gm 1:1 
16 Cefuroxime axetil +stearic acid 2gm 1:1 
17 Cefuroxime axetil + lactose anhydrous 2gm 1:1 
18 Cefuroxime axetil + MCC 2gm 1:1 
19 Cefuroxime axetil +HPMC 2gm 1:1 
20 Cefuroxime axetil +Neotame 1.25gm 1:0.25 
21 Cefuroxime axetil +HPC 2gm 1:1 
22 Cefuroxime axetil +sodium methyl    
paraben 
1.25gm 1:0.25 
23 Cefuroxime axetil +sodium propyl 
paraben 
1.25gm 1:0.25 
24 Cefuroxime axetil +sodium CMC 2gm 1:1 
  
 
7.2 INNOVATOR PRODUCT EVALUATION  
Cefuroxime axetil Oral suspension 250mg/5ml is available in market under the trade name 
Zinnat manufactured by Glaxo Smith Kline, UK Limited. The product was evaluated with 
respect to its taste, viscosity, fill weight and grittiness. The analytical parameters were also 
evaluated. 
 
SPECIFICATIONS OF CEFUROXIME AXETIL ORAL SUSPENSION AS PER USP 
Assay    90-110 % 
Water content    not more than 6 % 
pH    3.5 – 7.0 
Dissolution medium  0.07M Phosphate buffer 
Volume of medium  900 ml 
Apparatus   Type II paddle 
Rpm    50 
Duration    30 minutes 
Sample withdrawal  5 ml 
Limit     not less than 60 % in 30 minutes  
pH of media    7.0±0.1 
 
7.3 Development stages 
Different technologies have been used to address the problem of taste masking 
 
 
FORMULATION OF ORAL SUSPENSION  
In the present work three methods were adopted for taste masking of the bitter API to 
formulate the oral suspension.  
1. Addition of sweeteners and flavours 
2. Coating with stearic acid 
3. Complexation 
a) Beta cyclodextrin 
 
7.3.1 DETERMINATION OF THE AMOUNT OF DRUG REQUIRED TO BE USED 
TO FORMUALTE THE SUSPENSION  
Molecular weight of Cefuroxime is 424.4 g.  
Molecular weight of Cefuroxime Axetil is 510.48 g 
The amount of API required for each 5 ml of the suspension is based on the conversion 
factor calculated from HPLC assay and water content determined by Karl Fischer titration.
    
    100                                              100               
Conversion factor =                                         x 
Assay (anhydrous basis)         (100 - % water content ) 
 
Required quantity of drug     =  Conversion factor  ×  Label claim  
 
7.3.2 ADDITION OF SWEETENERS AND FLAVOURS 
The trial F1, F2, F3 employed sweetener and flavour technology of taste masking. The 
formulation is expressed below. 
TABLE 10: TRIAL F1, F2, F3  
S.no Ingredients F1  (mg) F2  (mg) F3 (mg) 
1. Cefuroxime axetil 298.500 298.500 298.500 
2. Sucrose  2634.500 2593.500 2595.500 
3. Aspartame  15.000 35.000 35.000 
4. Acesulfame K 25.000 25.000 25.000 
6. Xanthum gum 8.000 8.000 8.000 
7. Tutti frutti flavour 15.000 35.000 35.000 
8. Peppermint flavour 4.000 5.000 3.000 
 Weight per 5 ml 3000.000 3000.000 3000.000 
Manufacturing procedure  
1. API was sifted through sieve # 30.  
2. Sucrose was sifted through sieve # 30. 
3. All the other ingredients were passed through sieve # 40.  
4. The sugar was dried at 60˚C for one hour.  
5. Divided the sugar into two equal portions.  
6. The first portion of the sugar was milled and passed through sieve # 60. 
7. Geometrically mixed the milled sugar with the API. 
8. Geometrically mixed the excipients in step 3 with the above blend.  
9. The above portion was mixed with unmilled portion of sugar.    
10. The powder was blended thoroughly. 
11. Weighed and dispensed in bottles. 
 
7.3.3 COATING WITH STEARIC ACID 
Trial T1-T6 employed coating with stearic acid 
Coating specifications: 
Coating technique : Pan coating 
Inlet temperature    : 50°C-70°C 
Pan speed               : 3 rpm 
Spray rate            : 3ml/minute 
Atomization pressure : 1.2  kg/cm2 
 
COATING COMPOSITION -1 
TABLE 11 
S.NO INGREDIENTS QUANTITY (g) 
1. API 89.550 
2. Stearic acid 18.990 
3. PVP K30 2.151 
4. Isopropyl alcohol 25ml 
 
  
COATING COMPOSITION -2 
TABLE 12 
S.NO INGREDIENTS QUANTITY (g) 
1. API 98.325 
2. Lactose anhydrous 98.250 
3. Stearic acid 19.658 
4. PVP K30 0.393 
5. Isopropyl alcohol 35ml 
 
COATING COMPOSITION -3 
TABLE 13 
S.NO INGREDIENTS QUANTITY (g) 
1. API 98.325 
2. MCC pH 102 98.250 
3. Stearic acid 19.658 
4. PVP K30 0.393 
5. Isopropyl alcohol 35ml 
 
FORMULA FOR BLENDING:     
TABLE 14 
S.NO INGREDIENTS QNTY /5 ml (mg) QNTY /5 ml (mg) 
  T1 T2 
1. 
API:stearic acid 
granules 
366.000 
366.000 
2. Sucrose 2497.000 2531.000 
3. Xanthum gum 8.000 8.000 
4. Sodium lauryl sulphate 30.000 - 
5. Aspartame 35.000 35.000 
6. Acesulfame K 25.000 25.000 
7. Tutti frutti flavour 35.000 35.000 
8. Peppermint flavour 4.000  
 Weight / 5ml 3000.000 3000.000 
 
TABLE-15 
S.NO INGREDIENTS 
QNTY /5 
ml (mg) 
QNTY /5 
ml (mg) 
QNTY /5 
ml (mg) 
QNTY /5 
ml (mg) 
  T3 T4 T5 T6 
1. 
API:stearic acid 
granules 
366.000 
366.000 
 
366.000 
366.000 
2. Sucrose 2497.000 2531.000 2497.000 2531.000 
3. Xanthum gum 8.000 8.000 8.000 8.000 
4. 
Sodium lauryl 
sulphate 
30.000 
- 
30.000 
- 
5. Aspartame 35.000 35.000 35.000 35.000 
6. Acesulfame K 25.000 25.000 25.000 25.000 
7. Tutti frutti flavour 35.000 35.000 35.000 35.000 
8. Peppermint flavour 4.000  4.000  
 Weight / 5ml 3000.000 3000.000 3000.000 3000.000 
 
Manufacturing procedure 
1. The coating solution was prepared with the calculated composition. 
2. The solvent  was stirred under the mechanical stirrer for 5 minutes. 
3. Stearic acid  was added to the vortex of the solvent under stirring. Continued stirring 
for 10 minutes  
4. PVP K30 was added to the above solution and stirred for 10 minutes. 
5. The drug and the channeling agent was sifted through sieve # 60. 
6. The drug was preheated in the conventional coating pan. 
7. The spray solution was passed at a spray rate of 3ml/minute and an atomisation 
pressure of 1.2kg/cm2. Pan rpm was 3. 
8. After a time the spray was halted and allowed the granules to dry in a stream of hot 
air. 
9. The coated granules were sifted through sieve # 60.  
10. The granules were subjected to another coat of spray, dried the granules again.  
11. Sifted the granules through sieve # 40. 
12. The coated granules after cooling were used for formulation. 
13. The sugar was dried at 60˚C for one hour.  
14. Divided the sugar into two equal portions.  
15. The first portion of the sugar was milled and sifted through sieve # 60. 
16. Geometrically blended the milled sugar with the coated granule. 
17. Geometrically blended the excipients with the above blend.  
18. The above portion was mixed with unmilled portion of sugar.    
19. The powder was blend thoroughly.  
20. Weighed and dispensed in bottles. 
 
7.3.5. COMPLEXATION USING BETACYCLODEXTRIN 
CALCULATIONS FOR THE AMOUNT OF CEFUROXIME AXETIL 
REQUIRED PER 5 ml 
Molecular weight of cefuroxime axetil (CA) is 510.48 g 
Molecular weight of beta cyclodextrin (CD) is 1135 g 
Therefore, to prepare 1:1 ratio of drug: beta CD 
1g (1000mg) of drug CA  ≡  2.223 g (2223mg) of beta CD. 
The formulation development progressed with different trials each differing in one or the 
other parameter. Initially preliminary trials P1 to P9 were taken to optimize each 
parameter and then the final formulations P8 was developed. The formulations are listed 
below. 
 
 
 
 
 
 
 
  
 TABLE 16 : PRELIMINARY TRIALS P1 – P6 
 
The quantity of sucrose compensates the final average weight per 5ml.  
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO. INGREDIENTS P1(mg) P2(mg) P3(mg) P4(mg) P5(mg) P6(mg) 
1.  
CA:BetaCD 
complex 
962.066 962.066 962.066 962.066 962.066 962.066 
2. Sucrose 1934.934 1904.934 1934.934 1904.934 1934.934 1904.934
3. Ratio  1:1 1:1 1:1 1:1 1:1 1:1 
4. Water 100% 100%   50% 50% 
5. Isopropyl alcohol - - 100% 100% 50% 50% 
6. Xanthum gum 8.00 8.00   8.00 8.00 
7. 
Sodiumlauryl 
sulphate 
 30.00  30.00 - 30.00 
8. Aspartame 35 35 35 35 35.00 35.00 
9. Acesulfame K 25 25 25 25 25.00 25.00 
10. Tutti fruti flavour        35 35 35 35 35   35 
11. 
Avg weight in  
mg/5ml 
3000 3000 3000 3000 3000 3000 
COMPLEXATION USING BETA CYCLODEXTRIN WITH THE 
INCORPORATION OF SODIUM LAURYL SULPHATE:- 
TABLE-17 
SL NO INGREDIENTS QTY(mg) QTY(mg) QTY(mg) 
 FOR COMPLEXATION     P7      P8    P9 
1 Cefuroxime axetil 327.750 317.750 317.750 
2 Beta cyclodextrin 728.588 706.358 706.358 
3 SLS     6.000   15.000   30.000 
4 Water 100% 100% 100% 
 FOR BLENDING    
5 CA:B CD Complex 1086.772 1058.851 1072.028 
6 Sucrose 1812.228 1840.149 1826.972 
7 Acesulfame K    25.000    25.000    25.000 
8 Aspartame     35.000    35.000    35.000 
9 Xatham gum      6.000      6.000      6.000 
10 Tutti frutti flavour    35.000    35.000    35.000 
  3000.000 3000.000 3000.000 
 
  
Manufacturing procedure: 
1. The solvent was prepared . 
2. The solvent was stirred under the mechanical stirrer . 
3. The API and beta cyclodextrin were sifted through seive# 30,then transferred to 
solvent solution. 
4. Stirred for 6 hours. 
5. The formation of smooth slurry was obtained . 
6. The slurry was dried in the oven at 450c. 
7. Sifted the granules through sieve # 60. 
8. The granules after cooling were used for formulation. 
9. The sugar was dried at 60˚C for one hour.  
10. Divided the sugar into two equal portions.  
11. The first portion of the sugar was milled and sifted through sieve # 60. 
12. Sifted the excipients through seive# 40. 
13. Geometrically blended the milled sugar with the granule. 
14. Geometrically blended the excipients with the above blend.  
15. The above portion was mixed with unmilled portion of sugar.    
16. The powder was blend thoroughly.  
17. Weighed and dispensed in bottles. 
 
7.3.6 FORMULA OPTIMISATION  
Based on the preliminary formulations inferences are drawn and the trials are focused 
to optimise the formulation. 
 
  
TABLE  18: OPTIMIZED FORMULA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.4. EVALUATION OF ORAL SUSPENSION 
7.4.1 Taste Evaluation (Sensory Evaluation) 
Sensory evaluation is defined as a scientific discipline used to measure, analyze and 
interpret reactions to those characteristic of materials as they are perceived by the senses of 
sight, smell, taste, touch and hearing. 
 
Taste evaluation was done by taste panels. The method chosen was ranking test. For 
this purpose 10 human volunteers were selected. The suspension of the pure drug and 
formulations were coded and given to the volunteers. The intensity of bitterness was asked 
from volunteers. By using ranking test best taste masking technique was screened from all the 
adopted taste masking methods. Excellent ; good; fair ; bitter ; extremely bitter ; 
 
7.4.2 Mouth feel  
The mouth feel of the suspension is an important parameter with respect to its 
acceptance by the patient and thereby compliance. Gritty suspensions are usually not 
preferred. The data can be collected from the volunteers when given to taste.  
 
  
S.NO INGREDIENTS P8 
1. API 317.750 
2. Beta CD 706.358 
3. SLS 15.000 
4. Water 100% 
5 CA: B Cd complex 1058.581 
6. Sucrose            1840.149 
7. Aspartame 35 
8. Acesulfame K 25 
9. Xatham gum 6 
10. Tutti frutti flavour 35 
11. Avg weight in mg/5ml 3000 
7.4.3 Flow property    
This is measured in terms of angle of repose, bulk density, tapped density, 
compressibility index, hausner ratio which has been described earlier in section 7.1.4 
 
7.4.4. In vitro drug release studies 
Dissolution parameters of oral suspension 
Media       :   0.07M Phosphate buffer 
Volume of media     :   900ml  
Apparatus     :   Type II paddle 
Rpm      :   50 
Time       :   30 minutes 
Temperature     :   37.2± 0.5˚C 
 
Preparation of 0.07M phosphate buffer 
Dissolve 3.7g of monobasic sodium phosphate and 5.7g of anhydrous dibasic sodium 
phosphate in 1000ml water. 
 
Estimation of drug release using single external standard method: 
The in house specifications of the industry validates single external standard to be 
more accurate than the widely used calibration curve method for the estimation of drug 
content. The method even eliminates the possible errors like slightest variation in standard 
absorbance arising due to the differences in analytical working conditions on any particular 
analytical phase during the course of study.  The method requires the preparation of a 
working standard of cefuroxime axetil in the corresponding mediums in which the in vitro 
drug release studies are conducted during each particular trial of the study 
 
Preparation of standard 
Accurately weigh about 20 mg of the reference standard sample to a standard flask. 
Dissolve using small quantity of methanol. 10 ml of this solution is transferred to another 
standard flask. Make up with media to 100 ml. Observe for absorbance at 280 nm.  
 
 
Procedure of dissolution study 
The in vitro dissolution studies of cefuroxime axetil oral suspension is  performed 
using USP type II dissolution apparatus (paddle type). Test 5 ml of reconstituted cefuroxime 
axetil for oral suspension equivalent to  250 mg of cefuroxime. The dissolution medium 
consisted of 900ml of 0.07M phosphate buffer (pH=7.0) maintained at 37 ± 0.2°C. The speed 
of paddle was set at 50 rpm. Aliquot of samples (5ml) were withdrawn at specific time of 30 
minutes.  
 
Preparation of sample solutions: 
5ml of sample withdrawn was diluted with corresponding medium and made up to 
volume in a 100ml standard flask. The above solution was sonicated for 5mins and the 
absorbance was measured at 280nm.  
 
Measurement of absorbance in UV spectrometer:  
The amount of cefuroxime axetil released is determined by using an ultraviolet visible 
spectrophotometer at the wavelength of maximum absorbance at about 280 nm using the 
formulae below 
      wt. of std. * sample abs. * 900 * sample dilution * potency of std.                    
% Drug release =    
       std. dilution * std. absorbance * label claim     
                                                                                                                                                                            
7.4.5. Assay procedure for oral suspension 
The assay is carried out as per USP-NF.  
 
Standard preparation: Transfer about 30 mg of Cefuroxime Axetil to a 25 ml 
volumetric flask, dissolve in and dilute with methanol to volume and mix. Promptly transfer 
10 ml of this solution to a 50 ml volumetric flask, add 8.8 ml of methanol, dilute with 0.2M 
monobasic ammonium phosphate to volume and mix.  
 
Assay preparation: Transfer to a 100 ml volumetric flask an accurately measured 
portion of Cefuroxime axetil for oral suspension, freshly mixed and free from air bubbles, 
and equivalent to about 250 mg of cefuroxime. Add about 50 ml of methanol, and shake by 
mechanical means for about 10 minutes. Dilute with methanol to volume, and mix. Filter a 
portion of this stock solution, and transfer 5ml of the filterate to a 50 ml volumetric flask. 
Add 13.8ml of methanol, dilute with 0.2M monobasic ammonium phosphate to volume and 
mix.  
 
Procedure: Separately inject equal volumes of the standard preparation and the assay 
preparation into the chromatograph, record the chromatograms, and measure the responses.  
The chromatogram is recorded at 278 nm. 
 
Calculations of HPLC assay  
                                wt. of standard *mean sample area *specific gravity*dilution*potency*100 
 % Drug  
Content     =  
wt. of sample * mean std area 
 
7.4.6. DETERMINATION OF pH 
The determination of pH is an important tool as the formulation is reconstituted and 
used. By checking this we ensure any noticeable change during its use and storage.  
 
7.5  TASTE EVALUATION 
Taste evaluation is done by taste panels. The method chosen is ranking test. The 
suspension of the pure drug and formulations prepared by various techniques were coded and 
given to the volunteers. The intensity of bitterness was asked from volunteers. By using 
ranking test best taste masking technique was screened. 
 
7.6. DIFFERENTIAL SCANNING COLORIMETRY 
DSC studies were conducted to know the extent of complexation. DSC thermograms 
of pure drug, the complexing agent beta cyclodextrin, and the formulation were recorded and 
observed for peaks, for presence of additional peaks or absence of peaks indicating possible 
interactions or phase transformations. The thermal peaks give the melting points of the 
samples which can be used as a test for purity analysis and also for sample characterization. 
 
7.7.  pH STABILITY STUDY 
The formulation was studied for stability of pH. After reconstitution the suspension 
was stored at 2-8˚C and pH of the suspension was checked for 10 days  
 
7.8. SCALE UP  
Once the optimised formula was finalised a higher batch of the final formulation is 
taken by extrapolating the same formula for 100 bottles. 
 
7.9 STABILITY STUDIES  
 Short term accelerated stability studies are performed on the optimized formulations 
packed in HDPE bottles of 30ml capacity. The oral suspension is subjected to stability studies 
at 400C/75%RH in a stability chamber for a period of 1 month. Evaluation of the oral 
suspensions is done initially at the time of charging and at the end of first month. The 
suspensions are again analyzed for its physical appearance, water content and in vitro drug 
release profile and HPLC assay.   
  
MICROBIOLOGICAL ASSAY OF CEFUROXIME AXETIL 
 The microbiological assay of an antibiotic is based upon a comparison of the 
inhibition of growth of microorganism by measured concentrations of the antibiotics under 
examination with the product by known concentrations of a standard preparation of the 
antibiotic having a known activity. 
 The antimicrobial susceptibility of cefuroxime axetil oral suspension were tested by 
Kirby-Bauer antibiotic sensitivity test. 
 In this method filter paper disc of uniform size were impregnated with different 
concentrations of cefuroxime axetil and then placed on the surface of an agar plate that has 
been seeded with the organism to be tested .The efficacy of drug was determined by 
measuring the diameter of the zone of inhibition that results from diffusion of the drug into 
the medium surrounding the disc .The susceptibility of the organism to a drug was 
determined by the size of the zone. 
 
Media: 
Mueller Hinton Agar No-2: 
 The media consists of Caseine acid hydrolysate ,Beef heart infusion,Starch soluble 
and Agar. 
 
Preparation of media:  
 Suspend 38gms of Mueller Hinton Agar media in 1000ml distilled water, mixed well 
and heated to boiling to dissolve the medium completely. Then it was sterilized by 
autoclaving at 15lbs per square inch pressure at 1210c for 15 minutes. 
 
Organisms:  
 The test organisms selected were,Escherichia coli,Bacillus subtilis,salmonella typhi. 
 
Procedure: 
1. The covers of each of the agar plates were labeled with the name of the test organism 
to be inoculated. 
2. Using sterile techniques, all agar plates were inoculated with their respective test 
organisms as follows: 
a)  A sterile cotton swab was dipped into a well mixed saline test culture and 
excess inoculum was removed by pressing the saturated swab against the inner 
wall of the culture tube. 
b) Using the swab ,the entire agar surface were streaked horizontally,vertically 
and around the outer edge of the plate to ensure a heavy growth over the entire 
surface and all culture plates were allowed to dry for about 5 minutes. 
3. The individual discs were distributed on the respective points with sterile forceps. 
4. Each disc were gently pressed down with the sterile forceps to ensure that the discs 
adhere to the surface of the agar. 
5. All  the plates were incubated in an inverted position for 24 to 48 hours at 370c. 
6. Then the plates were examined for the presence of growth inhibition and the 
susceptibility of the organism to the drug was determined by the size of the zone.  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results and Discussion 
 
SECTION 8. RESULTS AND DISCUSSION  
8.1 EVALUATION OF API 
8.1.1Organoleptic properties of API 
Colour: Yellowish  
Odour: Nauseating 
Taste : Very bitter 
8.1.2 Particle size 
Initial weight of powder = 50 gms 
Final weight of powder = 41.39 gms 
Percentage of drug passed =  amount passed × 100 
     Initial weight 
           = 82.78% 
TABLE 19: PARTICLE SIZE DISTRIBUTION 
Sieve No. 
Aperture size 
(µm) 
Amount 
retained(g) 
Percentage 
retained(g) 
Cumulative 
Percentage 
retained 
20 850 0.00 0.00 0.00 
30 650 0.14 0.28 0.28 
40 425 1.48 2.96 3.24 
60 250 2.09 4.18 7.42 
80 180 2.89 5.78 13.20 
100 150 3.01 6.02 19.22 
Pan - 40.39 80.78 100.00 
 
 From the particle size analysis it is concluded that no particle was retained on sieve # 
20. Almost 81% of drug passes through all sieves. Hence not less than 80%of the   particles 
have size less than 150µm.  
 
8.1.3 Solubility 
 Solubility was studied in different solvents. Slightly soluble in water and ethanol and 
soluble in acetone, ethyl acetate and methanol.  
8.1.4 Flow property 
 The flow property is a measure of cohesiveness and flow of powder through a hopper during 
manufacturing.  
 
Angle of repose = 28˚ 
Bulk density = 0.165g/ml 
Tapped density = 0.238g/ml 
Hausner ratio = 1.444 
Compressibility index = 30.769 
8.2 PHYSICAL COMPATIBILITY STUDIES 
TABLE 20: DRUG EXCIPIENTS COMPATIBILITY REPORT 
SL.
NO. COMPOSITION 
DESCRIPTION 
INITIAL 2 WEEKS 4 WEEKS 
1 Cefuroxime axetil White to off white powder 
No colour 
change 
No colour 
change 
2 Cefuroxime axetil + Beta cyclodextrin 
White to off 
white powder 
No colour 
change 
No colour 
change 
3 
Cefuroxime axetil + Eudragit 
L 100 
White to off 
white powder 
No colour 
change 
No colour 
change 
4 Cefuroxime axetil + Xanthum gum 
White to off 
white powder 
No colour 
change 
No colour 
change 
5 Cefuroxime axetil + Colloidal Silicon Dioxide 
White to off 
white powder 
No colour 
change 
No colour 
change 
6 Cefuroxime axetil + Purified Talc 
White to off 
white powder 
No colour 
change 
No colour 
change 
7 Cefuroxime axetil + Sodium lauryl sulfate 
White to off 
white powder 
No colour 
change 
No colour 
change 
8 Cefuroxime axetil +Aspartame
White to off 
white powder
No colour 
change
No colour 
change 
09 Cefuroxime axetil +Sucralose White to off white powder 
No colour 
change 
No colour 
change 
10 Cefuroxime axetil + Acesulfame K 
White to off 
white powder 
No colour 
change 
No colour 
change 
12 Cefuroxime axetil + Sucrose White to off white powder 
No colour 
change 
No colour 
change 
13 Cefuroxime axetil + Peppermint flavor 
White to off 
white powder 
No colour 
change 
No colour 
change 
14 Cefuroxime axetil + Tutti frutti flavour  
White to off 
white powder 
No colour 
change 
No colour 
change 
15 Cefuroxime axetil + Citric acid  
White to off 
white powder 
No colour 
change 
No colour 
change 
16 Cefuroxime axetil +stearic White to off No colour No colour 
acid white powder change change 
17 Cefuroxime axetil +PVP K30 White to off white powder 
No colour 
change 
No colour 
change 
18 Cefuroxime axetil +Lactose anhydrous 
White to off 
white powder 
No colour 
change 
No colour 
change 
19 Cefuroxime axetil +MCC White to off white powder 
No colour 
change 
No colour 
change 
20 Cefuroxime axetil +HPMC White to off white powder
No colour 
change
No colour 
change 
21 Cefuroxime axetil +Neotame White to off white powder 
No colour 
change 
No colour 
change 
22 Cefuroxime axetil + HPC White to off white powder 
No colour 
change 
No colour 
change 
23 Cefuroxime axetil +sodium methyl paraben 
White to off 
white powder 
Slight 
brown 
colour 
change 
Slight 
brown 
colour 
change 
24 Cefuroxime axetil +sodium propyl paraben 
White to off 
white powder 
Slight 
brown 
colour 
change 
Slight 
brown 
colour 
change 
 
 From the above results,after 30 days of accelerated stability testing the drug excipient 
mixture remains unchanged except drug with Sodium methyl paraben and Sodium propyl 
paraben (shows slight brown colour change).Thus it was concluded that the excipients 
selected for the formulation were compatible with drug except sodium methyl paraben and 
sodium propyl paraben. 
 
8.3 INNOVATOR PRODUCT EVALUATION 
Label specification 
Product name Cefuroxime axetil granules for 100 ml 
Manufacturer Glaxo Smithkline Operations, UK ltd  
Brand name Zinnat suspension 
Labeled claim 250mg/5ml 
Lot no: C 451660 
Batch no. 9003354 
Mfg. Date 12/2009 
Exp. Date 12/2011  
Direction for reconstitution  : 
1. Shake bottle well to loosen granules. 
2. Fill the measuring cup to the line with 37 ml 
water. 
3. Add water to bottle in one go and replace 
cap.  
4. Invert and rock bottle vigorously (for at 
least 15 seconds) to mix medicine properly.  
5. To be used as directed by physician. Dose 
may be added to children’s cold fruit juices 
or milk immediately before taking. 
Storage instructions : 
Before reconstitution store below 30 ˚C. Kee
medicines out of reach of children. Once reconst
store in a refridgerator between 2 to 8 ˚C and use wit
days. Do no freeze. Contains aspartame. 
 
Evaluation report  
1. Taste   : pleasant initially, has slight bitter after taste  
2. Viscosity : adequate  
3. Grittiness  : gritty feeling  
4. Dissolution value  : 71.89% drug released    
5. Assay : 98 % 
 
 
8.3.1 AMOUNT OF CEFUROXIME AXETIL REQUIRED 
 The quantity of Cefuroxime axetil to be used in the formulation of a suspension 
containing 250 mg/ 5 ml was calculated from the assay value and the water content 
determined by Karl-Fischer method. 
 
Assay on anhydrous basis = 84.65 % 
Water content by KF titration = 1.04 % 
Conversion factor = 1.194 % 
The required amount of Cefuroxime axetil was calculated using the formula and was 
found to be 298.500mg.  
 
8.3.2 TASTE MASKING USING SWEETENERS AND FLAVOURS  
Trials F1 F2 F3 were carried out by applying the sweetener and flavour technology. 
TABLE 21: RESULTS OF TRIALS F1, F2, F3 
Parameters F 1 F 2 F 3 
Taste  Bitter   
Initially sweet; 
Bitterness  
persist 
 Bitter after taste 
Flavour Flavour is less 
Peppermint 
flavour 
predominates  
Flavour is ok 
Mouth feel Gritty  Slightly gritty Slightly gritty  
Pourability and 
viscosity 
Sufficient  Sufficient Sufficient 
Bulk density 0.769 0.744 0.76 
Tapped density 0.930 0.680 0.808 
Angle of repose 32.18 31.92 30.42 
Compressibility 
index 
17.307 8.571 6 
Hausner ratio 1.209 1.09 1.06 
Dissolution (%) 46.5 49 48.5 
pH 5.8 5.72 5.91 
 
FIGURE-2 DISSOLUTION PROFILE OF TRIALS F1,F2 &F3 
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Discussion  
Sucrose and aspartame are the two sweeteners used. Sucrose is used as a sweetening 
agent in beverages, foods, and pharmaceutical applications.  Flavours include Peppermint and 
Tutti frutti. In the formulation xanthum gum  acts as the viscosity building agent.  
 
In trial F1 15mg/5ml of aspartame were used. The bitter taste of drug persisted. Hence 
in trial F2 the amount of sweeteners was doubled. Flavour was less in both the trials. So the 
amount of both the flavour was increased in the third trial F3. A combination of all these was 
supposed to mask the bitter taste. The formulation was gritty in nature. Besides, caking or 
undissolved gel sediments were observed at the bottom of the dissolution bowl. This may be 
due to increase in percentage of xatham gum. So the percentage of xatham gum may be 
reduced in next trial .  
 
Conclusion  
The bitter taste still persist even after increasing the amount of sweetener and flavour; 
the average dissolution value falls far less than the expected limit of 60 %. Hence it was 
concluded that taste masking of Cefuroxime axetil oral suspension with sweetener and 
flavour technology was unsatisfactory. Therefore, alternate method was adopted in the next 
trial. 
 
  
8.3.3 TASTE MASKING BY COATING 
Trial T1-T6 employed coating of the drug particle with stearic acid, which is 
chemically octadecanoic acid. The results are tabulated below.  
TABLE-22 
Parameters T1 T2 T 3 T 4 T5 T6 
Taste Bitter    Bitter  
 Slightly 
Bitter 
 Slightly 
Bitter  
Bitter Bitter 
Flavour Sufficient Sufficient Sufficient Sufficient Sufficient Sufficient
Mouth feel Gritty Gritty Gritty Gritty Gritty Gritty 
Pourability and 
viscosity 
Sufficient  Sufficient Sufficient Sufficient 
Sufficient Sufficient
Bulk density 0.698 0.658 0.674 0.694 0.568 0.574 
Tapped density 0.796 0.768 0.758 0.790 0.698 0.658 
Angle of repose 31.28 32.41 32.82 32 30.98 31.10 
Compressibility 
index 
10.14 9.09 13.00 10.56 
13.33 13.62 
Hausner ratio 1.074 1.142 1.136 1.13 1.12 1.20 
Dissolution 32.32 29.12 65.97 53.55 43.40 42.41 
pH 5.36 6.28 6.47 6.25 6.24 6.18 
Assay 82 82.58 98.12 98.54 88 87.20 
 
 
  
FIGURE-3 DISSOLUTION PROFILE OF TRIALS T1-T6 
 
 
Discussion  
Large amount of drug and coating solution is required for coating. The formulation is 
gritty in nature. Hard granules were formed during coating process.  
 
Conclusion 
  The polymer is used in taste masking as it provides a barrier between the drug and the 
taste buds and reduces the drug solubility in saliva. In the present trial the feasibility of 
coating cefuroxime axetil with stearic acid is less in conventional coating pan. Large amount 
of drug and coating solution is required. Hence alternate method was adopted for the next 
trial. 
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8.3.5 TASTE MASKING BY INCLUSION COMPLEX FORMATION  
TABLE 23: RESULTS OF PRELIMINARY TRIALS P1-P6 
Parameters P 1 P 2 P 3 P 4 P5 P6 
Taste Bitter Bitter Slightly Bitter 
Slightly 
Bitter 
Slightly 
Bitter 
Slightly 
Bitter 
Flavour Sufficient Sufficient Sufficient Sufficient Sufficient Sufficient
Mouth feel Smooth Smooth Smooth Smooth Smooth Smooth 
Pourability and 
viscosity Sufficient Sufficient Sufficient Sufficient Sufficient Sufficient
Bulk density 0.689 0.75 0.689 0.776 0.749 0.769 
Tapped density 0.740 0.857 0.783 0.878 0.832 0.853 
Angle of repose 31.28 32.41 32.82 32 31.98 31.56 
Compressibility 
index 6.89 12.5 12 11.5 6.82 4.852 
Hausner ratio 1.074 1.142 1.136 1.13 1.09 1.12 
Dissolution 39.72 41.02 50 49.58 35.69 34.46 
pH 5.36 6.28 6.47 6.25 6.12 6.34 
 
FIGURE-4 DISSOLUTION PROFILE OF TRAILS P1-P6 
 
 
0
10
20
30
40
50
60
0 5 10 15 20 25 30 35
A
V
ER
A
G
E 
%
 O
F 
D
RU
G
 R
EL
EA
SE
D
TIME(MIN)
P1
P2
P3
P4
P5
P6
P6
 
TABLE 24: RESULTS OF PRELIMINARY TRIALS P7-P9 
Parameters P 7 P 8 P 9 
Taste Slightly bitter  Slightly bitter Slightly bitter 
Flavour Sufficient Sufficient Sufficient 
Mouth feel Smooth Smooth Smooth  
Pourability and 
viscosity 
Sufficient  Sufficient Sufficient 
Bulk density 0.769 0.777 0.709 
Tapped density 0.836 0.84 0.758 
Angle of repose 31.48 28 29.62 
Compressibility 
index 
8 7.4 6.45 
Hausner ratio 1.086 1.08 1.068 
Dissolution 66.61           75.77 75.70 
pH 6.45 6.38 6.15 
Assay 98.12 98.42 98 
 
FIGURE-5 DISSOLUTION PROFILE OF TRIALS P7-P9 
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Discussion  
Initial six trials were taken by without adding SLS to the complexation part.So the 
dissolution was not improving .But in the trials P7-P9 SLS was incorporated into the 
complexation part .Here  SLS improved the solubility of the Cefuroxime 
axetil:Betacyclodextrin complex.  
 
Conclusion 
  For initial 2 trials taste was not good,bitter taste and the dissolution was not in the 
limit .For trials P3-P6 taste was good,slightly bitter taste and the dissolution was not in the 
limit.For trails P7-P9 the taste was good,slight bitter after taste and the dissolution were 
increasing with increasing the concentration of SLS. In the case of P9 slight irritation on the 
throat occurs when increasing the SLS concentration.so P8 was choosen as best formulation. 
 
Inferences from preliminary trials: 
From the 9 preliminary trials certain inferences were drawn. They are as follows.   
1. The ideal ratio of drug : beta cyclodextrin was found to be 1: 1taken on weight basis. 
2. The fill weight was optimised at 3.0 grams per 5ml. 
3. The taste of the bitter drug is improved when iso propyl alcohol is used in the solvent. But 
dissolution of drug beta CD complex is bit hindered.   
4. Water is a good solvent with respect to dissolution. Hence a 100% water was taken as 
solvent. 
5. Ideal volume of complexing medium is 500 ml. 
6.  Ideal stirring time is 5-7 hrs.  
7. The  sweeteners along with sucrose contributes to taste abatement. 
8. Sodium lauryl sulphate enhances dissolution. 
9. A  30-35mg/5ml tutti frutti flavour works good at masking the bitter taste.   
10. As the pH of the formulation remains below 6.5 there was no need to add any buffer. 
  
8.3.6 FORMULA OPTIMIZATION  
TABLE 25 : RESULT OF OPTIMIZED FORMULA  
Parameters P8 
Taste Slightly bitter 
Flavour Sufficient 
Mouth feel Smooth 
Pourability and viscosity Sufficient 
Bulk density 0.777 
Tapped density 0.84 
Angle of repose 28 
Compressibility index 7.4 
Hausner ratio 1.08 
Dissolution (%)                   75.77 
pH 6.38 
Assay  98.42 
 
Trial P8 was chosen as the optimised formula. The bitter taste of the drug was masked 
to a larger extent by the complexation method . The flavour together with sweeteners have 
further improved the taste of the formulation. The average dissolution values lies at 75.77. 
The pH of the formulation was maintained below 6.38which omits the use of any buffer.  
FIG 6: DISSOLUTION PROFILE OF OPTIMIZED FORMULATION. 
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FIG 7: ASSAY OF OPTIMIZED FORMULA P8 
 
 
 
  
PACKING INSTRUCTION 
The dry powder for suspension is packed in HDPE bottles of 30 ml capacity. The 
bottles are sealed through induction sealing and labelled properly.  
 
DIRECTIONS FOR RECONSTITUTION 
1. Shake bottle well to loosen granules. 
2. Fill the measuring cup to the line with 18 ml water. 
3. Add water to bottle in one go and replace cap.  
4. Invert and rock bottle vigorously (for at least 15 seconds) to mix medicine properly.  
5. To be used as directed by physician. Dose may be added to children’s cold fruit juices 
or milk immediately before taking. 
STORAGE INSTRUCTION   
Suspension granules should be stored below 30°C.  
Multidose bottles : Store in cold condition after reconstitution at 2-8˚C. Do not use 
not more than 10 days after reconstitution.   
 
8.4 COMPARISON OF INNOVATOR PRODUCT WITH THE OPTIMZED 
FORMULATION  
The dissolution profile of the innovator product and the optimised formulation was 
compared and the results are shown below.  
 
TABLE 26: COMPARISON OF INNOVATOR PRODUCT WITH THE OPTIMZED 
FORMULATION 
Time (min) Average % drug released 
 Innovator product P8 
10 23.4 24 
20 44.6 46 
30 71.89 75.77 
 
  
FIG 8: COMPARISON OF DISSOLUTION PROFILE 
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8.5. TASTE EVALUATION: 
The efficacy of four methods in masking the bitter taste of Cefuroxime axetil was evaluated 
by taste panels using ranking test. 
TABLE 27:   TASTE EVALUATION REPORT 
 RANK  0 1 2 3 4 
Pure Drug 
  - - - - 9 
TASTE MASKING 
METHODS       
Addition of Flavors and 
Sweeteners 
F1 - - - 9  - 
F2 - - - 9  - 
F3 - - 9 - - 
Coating with stearic acid T1 - - 9 - - 
 
T2 - - 9 - - 
T3 - 9 - - - 
T4  9    
T5 - - 9 - - 
T6 - - 9 - - 
Complexation with β-
cyclodextrin 
P1 - - 9 - - 
P2 - - 9 - - 
P3 - 9 - - - 
P4 - 9 - - - 
P5 - 9 - - - 
P6 - 9 - - - 
Complexation with β-
cyclodextrin with the 
incorporation of SLS 
P7 9 - - - - 
 P8 9 - - - - 
 P9 9 - - - - 
Innovator product  9 - - - - 
 
0 = Acceptable; 1 = Slightly Bitter; 2= Bitter; 3 = Very Bitter, 4 = Extremely Bitter. 
 
 
 
 
 
8.6 DSC STUDY 
DSC study was carried out at the Sophisticated Analytical instruments Facility, STIC, 
Cochin University of Science and Technology, Cochin-22 using Mettler Toledo Star System 
model. DSC studies were conducted to know the extent of complexation. DSC thermograms 
of pure drug, the complexing agent beta cyclodextrin, and the formulation were recorded and 
observed for peaks, for presence of additional peaks or absence of peaks indicating possible 
interactions or phase transformations.  
 
FIG 9 : DSC DATA OF PURE API 
 
 
  
FIG 10: DSC DATA OF BETA CYCLODEXTRIN 
 
FIG 11: DSC DATA OF OPTIMISED FORMULATION 
 
 
  
OBSERVATION & CONCLUSION 
The thermogram of pure API shows a single sharp endothermic peak having a peak 
maximum of 83.36˚C with an onset temperature of 78.85˚C. DSC thermogram of complexing 
agent shows one endotherm of fusion, having a peak maximum of 139.53˚C. It showed a 
single, sharp, melting endotherm with an onset temperature of 109.74˚C. DSC curve of the 
optimised formulation shows a single endothermic peak of fusion, having a peak maximum 
of  143.23˚C.  
 
From the above thermograms it was concluded that the disappearance of API peak as 
well as the beta cyclodextrin peak in the thermogram of optimised formulation confirms 
complexation between Cefuroxime axetil and Beta cyclodextrin.  
 
8.7. pH STABILITY STUDY 
The dry powder after reconstitution were packed in HDPE bottles of 30 ml capacity 
and stored at 2-8˚C. The pH of the formulation was checked for 10 days. 
TABLE 28: pH STABILITY STUDY 
DAYS pH 
Day 1 6.38 
Day 2 6.09 
Day 3 6.42 
Day 4 6.55 
Day 5 6.48 
Day 6 6.32 
Day 7  6.55 
Day 8 6.46 
Day 9 6.50 
Day 10 6.50 
 
8.8.  SCALE UP STUDY 
The trial P8 was selected as the lead for the scale up. The composition of scale up 
batch is listed below. 
  
TABLE 29: COMPOSITION FOR SCALE UP 
 
SL NO INGREDIENTS Qty/5ml(mg) Qty/30ml(g) Qty/Batch in g 
 FOR 
COMPLEXATION 
   
1 Cefuroxime axetil 317.750 1.907 63.531 
2 Beta cyclodextrin 706.358 4.238 110.409 
3 Sodium lauryl sulphate 15.000 0.090 1.500 
4 Water 100% 100% 100% 
 FOR BLENDING    
5 CA:B CD Complex 1058.851 6.353 63.531 
6 Sucrose 1840.149 11.041 110.41 
7 Acesulfame K 25.000 0.150 1.500 
8 Aspartame 35.000 0.210 2.100 
9 Xatham gum 6.000 0.036 0.360 
10 Tutti frutti flavour 35.000 0.210 2.100 
  3000.000 18.00 180.000 
 
The scale up batch was an extention of the trial. The dry powders were filled into 
HDPE bottles of 30 ml capacity using dry syrup filling machine. The cap was sealed by 
induction sealing.  
 
8.9. STABILITY STUDIES  
Short term accelerated stability studies were performed on the optimized oral 
suspension formulations packed in HDPE bottles of 30 ml capacity. Fifty oral suspensions 
were subjected to stability studies at 400C/75% RH in a stability chamber for a period of 2 
months. Initial evaluation of the suspension was done and at the end of first and second 
month the suspensions were again analyzed for its physical appearance, assay, water content 
and in vitro drug release profile. 
 
Study conditions: 400C/75%RH 
Packing: HDPE bottles of 30 ml  
Equipment : Humidity chamber I- 0396 
TABLE NO. 30: ACCELERATED STABILITY STUDY REPORT 
PERIOD 
Dissolution 
(%) 
pH 
Assay 
(%) 
Appearance 
INITIAL 75.77 6.38 98.42 
White 
Colour 
1st MONTH 76.2 6.40 98.27 
White 
Colour 
2nd MONTH 78.1 6.52 97.2 
White 
Colour 
 
Conclusion : The accelerated stability studies reveal that the formulation has not 
undergone any physical or chemical degradation during the period. There are no significant 
differences in the in vitro drug release, pH and the drug content of the optimized formulation. 
              
 
 
 
 
  
ANTI MICROBIAL  ASSAY OF CEFUROXIME AXETIL 
 Three different wells were made in each petriplates for blank (B) and two 
dilutions(10-1and 10-2).Test sample was serially diluted in saline upto 10-2 dilutions.  
 
TABLE-31 
Sl.No Name of organism Diameter of inhibition zones in different 
dilutions of sample 
10-1 10-2 
1 E.coli 28mm 18mm 
2 Bacillus subtilis 23mm 9mm 
3 Salmonella typhi 22mm 15mm 
 
  
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
 
CONCLUSION 
 The bitter taste of drugs remains a big challenge to the pharma sector especially when 
it deals with oral pharmaceutical to paediatric population. Cefuroxime axetil is a betalactum 
antibiotic used for infections in the urinary tract, sinusitis, otitis media and so on. The highly 
bitter taste of drug reduces its patient compliance. In the present work the taste masking of 
the drug employed various techniques like masking with sweetener and flavour, drug particle 
coating  with stearic acid and finally complexation with betacyclodextrin.  
 Of this, inclusion complex formation with betacyclodextrin proved to be highly 
efficacious, cost effective and simple method. The drug is entrapped within the hydrophobic 
core of cyclodextrin thus reducing the solubility of drug in saliva. The complex is thought to 
separate inside the gastric environment thus releasing the drug. The drug is better absorbed 
from the upper part of intestine.  
 The complexation method is the most simplest method. All the formulation 
parameters were crucially scrutinised and optimised the final formula. DSC data of drug, 
complexing agent and optimised formulation confirms complexation. The suspension was 
taken on a scale up quantity and charged for stability studies. The report of the same has been 
furnished. The suspensions were evaluated as per USP standards. The in vitro studies of the 
suspension concludes here. Thus an attempt to mask the bitter taste of second generation 
cephalosporin antibiotic has been made.   
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